[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 165
1. Moon WS, Park HS, Yu KH, Jang KY, Kang MJ, Park H, Tarnawski AS: Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci; 2006 Apr;21(2):272-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis.
  • We examined expression of Ang-1, Ang-2, and their common receptor Tie2 mRNAs and proteins in gastric cancers using in situ hybridization and immunohistochemistry.
  • Ang-1 and Tie2 positivity correlated with advanced gastric cancers (p<0.05) and larger cancers had higher positive rates of Ang-1, Ang-2, and Tie2 mRNA expression (p<0.001, =0.010 and =0.039, respectively).
  • These findings indicate that the expression of Ang-1 and Ang-2 is important for tumor angiogenesis, and suggest a possible role of autocrine/paracrine function of angiopoietin/Tie2 system in gastric cancer progression.
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / blood supply. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Oct 15;86(8):1455-62 [10526273.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Br J Cancer. 2000 Nov;83(9):1154-60 [11027428.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1255-9 [11245414.001]
  • [Cites] Pathol Res Pract. 2001;197(2):101-7 [11261813.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2145-53 [11280779.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):918-27 [11309342.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5217-20 [11326698.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5736-40 [11479209.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):651-9 [11485923.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6248-54 [11507079.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):6-15 [11668472.001]
  • [Cites] Leuk Res. 2002 Feb;26(2):163-8 [11755466.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7124-9 [12460935.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):552-7 [12808060.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):168-75 [14757432.001]
  • [Cites] Histopathology. 2004 Mar;44(3):232-9 [14987226.001]
  • [Cites] J Hepatol. 2004 May;40(5):799-807 [15094228.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1557-70 [15509526.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):598-603 [1311287.001]
  • [Cites] Oncogene. 1993 May;8(5):1293-301 [8386827.001]
  • [Cites] Growth Factors. 1993;9(2):99-105 [8217221.001]
  • [Cites] J Pathol. 1996 Jul;179(3):232-7 [8774475.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1161-9 [8980223.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1171-80 [8980224.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):545-50 [9355979.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):594-9 [9778629.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • (PMID = 16614513.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ PMC2734003
  •  go-up   go-down


2. Omori M, Hashi A, Ishii Y, Yuminamochi T, Nara M, Kondo T, Hirata S, Katoh R, Hoshi K: Clinical impact of preoperative screening for gastric mucin secretion in cervical discharge by HIK1083-labeled latex agglutination test. Am J Clin Pathol; 2008 Oct;130(4):585-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of preoperative screening for gastric mucin secretion in cervical discharge by HIK1083-labeled latex agglutination test.
  • The present study evaluated the clinical impact of preoperative screening for gastric mucin in cervical discharge, using a latex agglutination test with HIK1083, a monoclonal antibody against gastric mucin.
  • Glandular lesions with a gastric phenotype were identified histologically in all 26 cases positive for the HIK1083 latex test, such as minimal deviation adenocarcinoma, lobular endocervical glandular hyperplasia (LEGH), and pyloric gland metaplasia, but not in negative cases.
  • In 2 cases of LEGH, adenocarcinoma in situ was identified.
  • Screening of gastric mucin in cervical discharge may facilitate preoperative detection of some early cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Gastric Mucins / analysis. Latex Fixation Tests. Uterine Cervical Neoplasms / diagnosis. Vaginal Discharge / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794052.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastric Mucins
  •  go-up   go-down


3. Furuya T, Uchiyama T, Adachi A, Chochi Y, Oga A, Kawauchi S, Ishiglo K, Sasaki K: Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas. Oncol Rep; 2006 Jun;15(6):1491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas.
  • We analyzed DNA copy number aberrations (DCNAs) by chromosomal comparative genomic hybridization (CGH) in 93 consecutive sporadic gastric adenocarcinomas.
  • In addition, numerical aberrations in chromosomes 7, 11, 17, and 18 were evaluated by fluorescence in situ hybridization (FISH).
  • Gastric cancers were divided on the basis of nuclear DNA content measured by laser scanning cytometry (LSC) into two groups, 36 DNA diploid (1.0 <or= DNA index (DI) < 1.2) and 57 aneuploid (DI >or= 1.2) cancers.
  • These data indicate that gastric adenocarcinomas can be divided into three types; aneuploid, major diploid type and diploid subtype cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Ploidies. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685384.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


Advertisement
4. Rugge M, Fassan M, Zaninotto G, Pizzi M, Giacomelli L, Battaglia G, Rizzetto C, Parente P, Ancona E: Aurora kinase A in Barrett's carcinogenesis. Hum Pathol; 2010 Oct;41(10):1380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Barrett's mucosa, both aneuploidy and TP53 mutations are consistently recognized as markers of an increased risk of Barrett's adenocarcinoma.
  • Eighty-seven esophageal biopsy samples representative of all the phenotypic lesions occurring in the multistep process of Barrett's carcinogenesis (gastric metaplasia in 25, intestinal metaplasia in 25, low-grade intraepithelial neoplasia in 16, high-grade intraepithelial neoplasia in 11, and Barrett's adenocarcinoma in 10) were obtained from long segments of Barrett's mucosa.
  • AURKA overexpression is significantly associated with Barrett's mucosa progressing to Barrett's adenocarcinoma and contributes to esophageal carcinogenesis via chromosome instability.
  • [MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Cell Transformation, Neoplastic / metabolism. Esophageal Neoplasms / enzymology. Esophagus / enzymology. Protein-Serine-Threonine Kinases / biosynthesis
  • [MeSH-minor] Aurora Kinase A. Aurora Kinases. Carcinoma in Situ / enzymology. Carcinoma in Situ / pathology. Cell Nucleus Size. Gastric Mucosa / enzymology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Intestinal Mucosa / pathology. Metaplasia. Mucous Membrane / enzymology. Mucous Membrane / pathology. Oligonucleotide Array Sequence Analysis. Retrospective Studies. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20656315.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


5. Geddert H, Zur Hausen A, Gabbert HE, Sarbia M: EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol (Amst); 2010;33(3):143-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1.
  • BACKGROUND: Epstein-Barr virus (EBV)-associated gastric carcinomas (GC) constitute a distinct clinicopathological entity of gastric cancer.
  • METHODS: One hundred GC were tested by RNA-in situ hybridization for the presence of EBV by EBV-encoded small RNA (EBER).
  • Our data add new insights to the role of EBV in gastric carcinogenesis and underline that EBV-associated GC comprise a distinct molecular-pathologic as well as a distinct clinicopathological entity of GC.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / virology. Adult. Aged. Aged, 80 and over. Epstein-Barr Virus Infections / genetics. Epstein-Barr Virus Infections / physiopathology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20978327.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / APC protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p14ARF
  • [Other-IDs] NLM/ PMC4605817
  •  go-up   go-down


6. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P: Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol; 2010 Dec;34(12):1868-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her-2-targeted therapy has recently been shown to be beneficial for patients with advanced gastric cancer.
  • HER-2 gene amplification was assessed by colorimetric in-situ hybridization.
  • [MeSH-major] Adenocarcinoma / secondary. Barrett Esophagus / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Esophagogastric Junction / metabolism. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Gene Amplification. Gene Expression. Humans. In Situ Hybridization. Prognosis. Survival Rate


7. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology; 2008 Jun;52(7):797-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
  • Validated methods and scoring systems for evaluating HER2 status exist in breast cancer, but not in gastric cancer.
  • The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrollment in a trial of trastuzumab (Herceptin) in advanced metastatic gastric cancer.
  • METHODS AND RESULTS: Formalin-fixed paraffin-embedded gastric cancer samples were tested for HER2 status using the fluorescence in situ hybridization (FISH) pharmDxt kit (Dako Denmark A/S).
  • CONCLUSIONS: IHC/FISH discrepancies were attributed to basolateral membranous immunoreactivity of glandular cells resulting in incomplete membranous reactivity and/or a higher rate of tumour heterogeneity in gastric cancer compared with breast cancer.
  • With modifications to the IHC scoring system, the HercepTest is considered valid for the identification of HER2+ gastric tumours for this clinical trial.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Consensus. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Reproducibility of Results


8. Ma TY, Liu WK, Chu YL, Jiang XY, An Y, Zhang MP, Zheng JW: Detection of human papillomavirus type 16 DNA in formalin-fixed, paraffin-embedded tissue specimens of gastric carcinoma. Eur J Gastroenterol Hepatol; 2007 Dec;19(12):1090-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human papillomavirus type 16 DNA in formalin-fixed, paraffin-embedded tissue specimens of gastric carcinoma.
  • OBJECTIVES: Human papillomavirus type 16 (HPV16) is regarded as one of the important tumor-related viruses, which are known to have a role in cervical carcinoma; however, there are few reports on HPV16 in gastric carcinoma (GC).
  • METHODS: Liquid PCR (LPCR) and in-situ PCR (ISPCR) methods were carried out to detect the HPV16 oncogene E6 cell-type-specific enhancer in the long control region of HPV16 in 40 GCs and corresponding gastric adjacent normal mucosa (GANM).
  • The patients were from Shaanxi Province in China; Helicobacter pylori (Hp) was detected by immunohistochemistry and by hematoxylin and eosin staining in their gastric tissues.
  • HPV16 DNA was mainly located in the nucleus of gastric glandular epithelium cells.
  • CONCLUSIONS: These findings suggested that HPV16 can infect gastric glandular epithelium cells and that viral infection might play a role in the occurrence of GCs independent of or without the cooperation of an Hp infection.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998834.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins
  •  go-up   go-down


9. Ahn BJ, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS: Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. Eur J Clin Pharmacol; 2010 Dec;66(12):1235-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
  • METHODS: Pharmacokinetic data obtained from 16 gastric adenocarcinoma patients with peritoneal seeding were used.
  • CONCLUSIONS: Our results demonstrate that a small fraction of intraperitoneally administered CPT-11 was metabolized in situ to active SN-38 and that the Vss of plasma CPT-11 following IP administration in our patient cohort was lower than that estimated in previous reports following the intravenous administration of CPT-11.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):175-84 [10676997.001]
  • [Cites] Jpn J Cancer Res. 1995 Jan;86(1):111-6 [7737902.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2182-94 [11489791.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4187-91 [10628373.001]
  • [Cites] Clin Chem. 2003 Nov;49(11):1900-8 [14578322.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3293-301 [12149304.001]
  • [Cites] Ther Drug Monit. 2005 Aug;27(4):536-8 [16044114.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2747-54 [9829738.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):141-51 [7786822.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Jan;67(1):5-11 [20213078.001]
  • [Cites] Drug Metab Dispos. 2000 Apr;28(4):423-33 [10725311.001]
  • [Cites] J Med Chem. 1994 Jan 7;37(1):40-6 [8289200.001]
  • [Cites] Clin Pharmacokinet. 1997 Oct;33(4):245-59 [9342501.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):133-40 [7786821.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 25;795(1):25-34 [12957166.001]
  • [Cites] AAPS J. 2011 Jun;13(2):143-51 [21302010.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):165-70 [9654118.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(12 ):2188-90 [12484033.001]
  • [Cites] Clin Pharmacol Ther. 2002 Dec;72 (6):638-47 [12496745.001]
  • [Cites] Biomed Chromatogr. 2003 Dec;17 (8):493-9 [14648604.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Oct;28(11):1505-7 [11707965.001]
  • (PMID = 20827550.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Fukayama M: Epstein-Barr virus and gastric carcinoma. Pathol Int; 2010 May;60(5):337-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus and gastric carcinoma.
  • Epstein-Barr virus (EBV) has been accepted as an infective agent causing gastric carcinoma (GC).
  • Sequential events in the gastric mucosa could be traced from EBV infection of the pit cells to fully developed carcinomas by EBV encoded small RNA (EBER)-in situ hybridization.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Stomach Neoplasms / virology
  • [MeSH-minor] Cell Line, Tumor. CpG Islands / genetics. Gene Expression Regulation. Gene Silencing. Host-Pathogen Interactions. Humans. In Situ Hybridization. Methylation. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. RNA, Neoplasm / analysis. RNA, Viral / analysis. Viral Matrix Proteins / genetics. Viral Matrix Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518883.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Neoplasm; 0 / RNA, Viral; 0 / Viral Matrix Proteins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 84
  •  go-up   go-down


11. Wang YZ, Cao YQ, Wu JN, Chen M, Cha XY: Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gastroenterol; 2005 Jan 7;11(1):46-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA.
  • AIM: To investigate the expression of NOS in gastric carcinoma, and to explore the relationship between the expression of nitric oxide synthases (NOS) and p53, PCNA, pathological features and clinical staging of gastric cancer.
  • METHODS: The activity of NOS protein was investigated in 85 samples of human gastric carcinoma and 25 samples of normal gastric mucosal tissue by biochemical assay.
  • We then examined the expression of NOS, p53, PCNA in 85 samples of human gastric cancer was examined by immunohistochemistry, and NOS mRNA expression in 85 gastric cancer tissue specimens by in situ hybridization.
  • RESULTS: Biochemical assay showed that the activity of NOS was significantly higher in gastric carcinoma than in normal gastric mucosal tissues (t = 0.4161, P<0.01).
  • Immunohistochemistry revealed that endothelial nitric oxide synthase (eNOS) expressed in all samples of normal gastric mucosa, but only 6 cases of 85 gastric cancer specimens showed weak positive immunohistochemical reactions to eNOS (20%).
  • Inducible nitric oxide synthase (iNOS) was expressed strongly in human gastric carcinoma (81.2%).
  • In situ hybridization analysis showed that iNOS mRNA expression was significantly stronger than eNOS mRNA expression in gastric cancer tissue (chi(2) = 10.23, P<0.01).
  • The expression of iNOS in gastric cancer was associated with differentiation, clinical stages or lymph node metastases (r = 0.3426, P<0.05).
  • The expression of neuronal nitric oxide synthase (nNOS) was not examined by immunohistochemistry and in situ hybridization in gastric cancer specimens and normal gastric mucosa.
  • CONCLUSION: In human gastric cancer, there is an enhanced expression of iNOS, but not of eNOS.
  • NOS promotes the proliferation of tumor cells and plays an important role in gastric cancer spread.
  • Inactivation of antioncogene p53 and overexpression of iNOS might play a synergetic role in the process of carcinogenesis of human gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / physiopathology. Nitric Oxide Synthase / genetics. Proliferating Cell Nuclear Antigen / metabolism. Stomach Neoplasms / physiopathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Lymphatic Metastasis. Male. Middle Aged. Nitric Oxide Synthase Type II

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609395.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4205382
  •  go-up   go-down


12. Wang LL, Yao GY, Zhang BY, Zhang XM, Zhao M: [Expression and significance of CD147 and E-cadherin in human gastric carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of CD147 and E-cadherin in human gastric carcinoma].
  • OBJECTIVE: To investigate the expression of CD147 and E-cadherin in gastric carcinoma and their correlation with clinicopathological features.
  • METHODS: The expression of CD147 and E-cadherin in gastric cancer tissue chip (TC) was detected by in situ hybridization (ISH) and immunohistochemistry in 220 cases of gastric carcinoma and 31 cases with normal gastric mucosa.
  • CONCLUSION: In gastric carcinoma, up-regulation of CD147 and down-regulation of E-cadherin are in a negative correlation.
  • The examination of both these two factors together is useful for predicting the invasion and metastasis of gastric cancer, therefore, can be used as a significant marker to direct clinic therapy and estimation of prognosis.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Antigens, CD147 / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / metabolism. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


13. Lisovsky M, Dresser K, Woda B, Mino-Kenudson M: Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Hum Pathol; 2010 Jun;41(6):902-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias.
  • Pancreatic intraepithelial neoplasia is a precursor to ductal adenocarcinoma of the pancreas that shows gastric differentiation.
  • Pancreatic intraepithelial neoplasia-3 has the highest potential to progress to adenocarcinoma, and its distinction from lower-grade pancreatic intraepithelial neoplasias is important for clinical management.
  • A product of cell polarity gene lethal giant larvae 2 is a marker of gastric foveolar epithelium expressed in a basolateral fashion, which is lost or mislocalized in gastric epithelial dysplasia and adenocarcinoma.
  • In this study, we investigated a role of lethal giant larvae 2 expression in differentiating low-grade pancreatic intraepithelial neoplasias, that is, pancreatic intraepithelial neoplasia-1 and pancreatic intraepithelial neoplasia-2, from pancreatic intraepithelial neoplasia-3 and pancreatic ductal adenocarcinoma.
  • Conversely, all lesions of pancreatic intraepithelial neoplasia-3 and adenocarcinoma showed loss of lethal giant larvae 2 staining and/or its cytoplasmic localization.
  • In conclusion, our results show that low-grade pancreatic intraepithelial neoplasias express lethal giant larvae 2 in a basolateral fashion recapitulating expression in normal gastric epithelium.
  • Loss or abnormal lethal giant larvae 2 expression is seen in pancreatic intraepithelial neoplasia-3 and adenocarcinoma and might be useful in separating them from lower-grade pancreatic intraepithelial neoplasias.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Cytoskeletal Proteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Cell Polarity. Diagnosis, Differential. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Pancreas / metabolism. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20233622.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


14. Aurello P, Rossi S, D'Angelo F, Nigri G, Cicchini C, Ciardi A, Coluccia P, Ercolani G, Cescon M, Cucchetti A, Ravaioli M, Del Gaudio M, Ramacciato G: [Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer]. Chir Ital; 2007 Jul-Aug;59(4):435-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer].
  • Angiogenic factors and apoptosis were studied immunohistochemically in 72 gastric cancer cases.
  • [MeSH-major] Adenocarcinoma / secondary. Apoptosis. Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Stomach Neoplasms / pathology. Transforming Growth Factor alpha / analysis. Vascular Endothelial Growth Factors / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor C / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966762.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transforming Growth Factor alpha; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


15. Kim J, Kim MA, Jee CD, Jung EJ, Kim WH: Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int J Cancer; 2009 Oct 15;125(8):1842-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma.
  • In the present study, array based comparative genomic hybridization (CGH) was used to screen DNA copy number change in gastric cancer cell lines and the results obtained were compared with oligonucleotide microarray data.
  • DNA loss of the ANXA10 locus in chromosome 4q33 was found in several gastric cancer cell lines by array based CGH and these cell lines showed decreased ANXA10 expression by oligonucleotide microarray analysis.
  • Functional analysis using siRNA and full-length cDNA transfection in gastric cancer cell lines demonstrated that ANXA10 regulates gastric cancer cell proliferation.
  • Of the 585 primary gastric carcinoma tissues examined, ANXA10 expression at the protein level was found to be reduced in 289 (49.4%) cases.
  • Quantitative real-time PCR analysis validated loss of DNA at the ANXA10 locus in gastric carcinomas with reduced ANXA10 expression.
  • These results suggest that ANXA10 inactivation by chromosomal deletion may play a role during gastric cancer progression.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Apoptosis. Blotting, Western. Case-Control Studies. Cell Movement. Cell Proliferation. Cells, Cultured. Chromosome Mapping. Chromosomes, Human, Pair 4 / genetics. Colony-Forming Units Assay. Comparative Genomic Hybridization. Female. Gene Expression Profiling. Humans. Immunoblotting. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Kidney / embryology. Kidney / metabolism. Kidney / pathology. Lymphatic Metastasis. Male. Mutation / genetics. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Stomach / metabolism. Stomach / pathology. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582876.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANXA10 protein, human; 0 / Annexins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


16. Koorstra JB, Feldmann G, Habbe N, Maitra A: Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg; 2008 Jul;393(4):561-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Pancreatic ductal adenocarcinoma (i.e., pancreatic cancer) is an almost universally lethal disease.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Aug;2(2):149-55 [12204535.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):6-13 [12573429.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Apr;5(2):133-40 [12631453.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2585-8 [12750283.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Arch Dermatol. 2003 Aug;139(8):1019-25 [12925390.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:15 [12605716.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):651-7 [15277238.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Bull Osaka Med Coll. 1990 Nov;36(1-2):1-11 [2135640.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5087-9 [8221640.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3025-33 [8187092.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1708-11 [8194721.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11544-8 [8524800.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Development. 1996 Mar;122(3):983-95 [8631275.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5360-4 [8968085.001]
  • [Cites] J Pathol. 1996 Oct;180(2):160-5 [8976874.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1634-7 [9134998.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):363-9 [9663429.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):89-93 [15626591.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2485-90 [15861417.001]
  • [Cites] Mol Cancer Res. 2005 Jul;3(7):413-23 [16046552.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):97-101 [16169155.001]
  • [Cites] CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50 [16449183.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 [16858539.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):155-62 [17297654.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]
  • [Cites] Mol Imaging. 2007 Mar-Apr;6(2):131-9 [17445507.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S61-70 [17486053.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Mini Rev Med Chem. 2007 Jun;7(6):599-608 [17584158.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R88-95 [17613553.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):238-44 [18157091.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2495-504 [10861425.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):266-73 [11561603.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12683-8 [11675499.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8830-7 [11751405.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):798-802 [11787853.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1361-9 [11943721.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(6):544-8 [11956906.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]
  • [Cites] Trends Mol Med. 2002 Jun;8(6):288-93 [12067615.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4301-6 [12082617.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]
  • [Cites] Harvey Lect. 2000-2001;96:73-92 [12200872.001]
  • (PMID = 18283486.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113669-02; United States / NCI NIH HHS / CA / R01 CA113669-01; United States / NCI NIH HHS / CA / CA113669-02; United States / NCI NIH HHS / CA / CA113669-04; United States / NCI NIH HHS / CA / CA113669-03; United States / NCI NIH HHS / CA / R01 CA113669-05; United States / NCI NIH HHS / CA / R01 CA113669-03; United States / NCI NIH HHS / CA / R01 CA113669; United States / NCI NIH HHS / CA / R01 CA113669-04; United States / NCI NIH HHS / CA / CA113669-05; United States / NCI NIH HHS / CA / CA113669-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Gastric Mucins; 0 / KRAS protein, human; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / apomucin; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 104
  • [Other-IDs] NLM/ NIHMS98193; NLM/ PMC2666329
  •  go-up   go-down


17. Terada T: Esophageal Cancers: A Clinicopathologic and Immunohistochemical Study of 223 Cases. Gastroenterology Res; 2009 Jun;2(3):148-151
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The number and frequency (percentages) were as follows: 54 mild dysplasia (5.7%), 30 moderate dyplasia (3.2%), 32 severe dysplasia (3.4%), 13 carcinoma in situ (1.4%), 71 squamous cell carcinoma (7.5%), 7 primary adenocarcinoma (0.7%), 1 primary signet ring cell carcinoma (0.1%), 4 primary small cell carcinoma (0.4%), 2 primary amelanotic malignant melanoma (0.2%), 1 primary undifferentiated sarcoma (0.1%), 7 gastric cancer invasion (0.7%), and 1 primary adenoid cystic carcinoma (0.1%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27933124.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Benign lesions / Clonicopathologies / Esophagus / Immunohistochemistry / Malignant lesions
  •  go-up   go-down


18. von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M: No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog; 2006 May;45(5):349-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr Virus (EBV) infection is considered to play an etiologic role in human malignancies, including a subset of gastric and cardiac cancers.
  • We have investigated the prevalence of EBER expression (EBV-encoded small RNAs) in a series of small bowel adenocarcinomas (n=56) utilizing RNA in situ hybridization (EBER-RISH).
  • A surgical series of 82 primary resected gastric (n=36) or cardiac (n=46) adenocarcinomas (TU Munich) was used as control group.
  • None of the 56 small bowel carcinomas exhibited EBER expression whereas in the control group the rate of EBER expression accounted for 4.4% in the group of cardia carcinomas and 8.6% in the group of gastric cancers.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Intestinal Neoplasms / virology. Intestine, Small / virology. Stomach Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16493667.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


19. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, Zhao P: Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol; 2005 Feb 7;11(5):629-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas.
  • AIM: To understand the expression of latent and lytic genes of Epstein-Barr virus (EBV) in EBV-associated gastric carcinoma (EBVaGC) and to explore the relationship between EBV-encoded genes and development of EBVaGC at molecular level.
  • METHODS: One hundred and seventy-two gastric carcinoma tissues and 172 corresponding para-carcinoma tissues were tested for EBV genome by polymerase chain reaction (PCR)-Southern blotting.
  • EBV-encoded small RNA (EBER) 1 of the PCR positive specimens was detected by in situ hybridization (ISH).
  • Gastric carcinomas with positive EBER1 signals were classified as EBVaGCs.
  • RESULTS: Eleven EBV positive samples existed in gastric carcinoma tissues (6.39%).
  • CONCLUSION: The latent pattern of EBV in gastric carcinoma corresponds to the latency I/II.
  • BARF1 and BHRF1 genes may play an important role in tumorigenesis of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / genetics. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Herpesvirus 4, Human / genetics. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655811.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250728
  •  go-up   go-down


20. Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, Lauwers GY, Booker JK, Gulley ML: High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Lab Invest; 2009 Jan;89(1):80-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma.
  • Gastric adenocarcinoma is the second leading cause of cancer death worldwide.
  • It is unclear whether EBV is being missed in some gastric adenocarcinomas due to insensitive test methods or partial EBV genome loss.
  • In this study, we screened 113 gastric adenocarcinomas from low- and high-incidence regions (United States and Central America) for the presence of EBV using a battery quantitative real-time PCR (Q-PCR) assays targeting disparate segments of the EBV genome (BamH1W, EBNA1, LMP1, LMP2, BZLF1, EBER1) and histochemical stains targeting EBV-encoded RNA (EBER), the latent proteins LMP1 and LMP2, and the lytic proteins BMRF1 and BZLF1.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2008;43(6):669-74 [18569983.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):149-52 [12777999.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):1059-62 [12792770.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1244-9 [14557970.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7062-7 [14612496.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] Herpes. 2003 Dec;10(3):78-82 [14759340.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1698-705 [15014022.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):34-6 [15027715.001]
  • [Cites] Gastric Cancer. 2004;7(1):9-16 [15052434.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Oncol Rep. 2004 Sep;12(3):543-7 [15289835.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):87-94 [15361640.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):805-9 [8039108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] APMIS. 1994 Jul;102(7):495-500 [7917218.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):625-31 [8761381.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):155-8 [9139835.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):730-4 [9361110.001]
  • [Cites] J Pathol. 1997 Nov;183(3):293-8 [9422984.001]
  • [Cites] Arch Virol. 1997;142(9):1743-56 [9672634.001]
  • [Cites] Int J Mol Med. 1998 Jan;1(1):137-42 [9852211.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):941-7 [10487851.001]
  • [Cites] J Virol. 2004 Dec;78(24):13470-8 [15564458.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):27-30 [15609391.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3234-9 [15929173.001]
  • [Cites] J Virol. 2005 Nov;79(22):13984-92 [16254334.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):288-97 [16247482.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2689-94 [16477006.001]
  • [Cites] Methods Mol Biol. 2006;326:115-37 [16780197.001]
  • [Cites] J Pathol. 2006 Aug;209(4):430-5 [16710842.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Sep;4(9):1103-11 [16820326.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1193-205 [17049016.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] Korean J Intern Med. 2004 Mar;19(1):43-7 [15053043.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):487-91 [15113855.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):45-50 [10665912.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):69-75 [11263593.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1856-9 [11448896.001]
  • [Cites] Intern Med J. 2001 Jul;31(5):296-303 [11512601.001]
  • [Cites] Microsc Res Tech. 2001 Jun 15;53(6):409-13 [11525258.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):781-6 [11891176.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1920-6 [11912175.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):870-7 [12181273.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):825-9 [12190097.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4876-8 [12208733.001]
  • [Cites] J Pathol. 2002 Aug;197(5):684-8 [12210090.001]
  • [Cites] Diagn Mol Pathol. 2002 Sep;11(3):127-34 [12218450.001]
  • [Cites] J Virol. 2002 Nov;76(21):10951-9 [12368338.001]
  • [Cites] Int J Mol Med. 2002 Nov;10(5):635-9 [12373307.001]
  • [Cites] Neoplasma. 2003;50(1):8-12 [12687272.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2942-9 [16835376.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] Trans Am Clin Climatol Assoc. 2006;117:55-73; discussion 73-4 [18528464.001]
  • (PMID = 19002111.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR1667; United States / NIEHS NIH HHS / ES / ES007017-34; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NIDDK NIH HHS / DK / P30 DK 034987; United States / NIEHS NIH HHS / ES / T32 ES007017; United States / NIEHS NIH HHS / ES / T32-ES07017; United States / NIEHS NIH HHS / ES / T32 ES007017-34
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Protein Isoforms; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ NIHMS68618; NLM/ PMC2612099
  •  go-up   go-down


21. Li X, Zhang YY, Wang Q, Fu SB: Association between endogenous gene expression and growth regulation induced by TGF-beta1 in human gastric cancer cells. World J Gastroenterol; 2005 Jan 7;11(1):61-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between endogenous gene expression and growth regulation induced by TGF-beta1 in human gastric cancer cells.
  • AIM: To investigate the association between endogenous gene expression and growth regulation including proliferation and apoptosis induced by transforming growth factor-beta1 (TGF-beta1) in human gastric cancer (GC) cells.
  • The apoptotic cells were visualized by means of the terminal deoxynucleotidyl transferase (TdT)-mediated dTUP in situ nick end-labeling (TUNEL) method.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic / drug effects. Stomach Neoplasms / genetics. Transforming Growth Factor beta / pharmacology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609398.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / SMAD7 protein, human; 0 / Smad7 Protein; 0 / TGFB1 protein, human; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC4205385
  •  go-up   go-down


22. Ma XL, Sun HJ, Wang YS, Huang SH, Xie JW, Zhang HW: Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol; 2006 Jul 7;12(25):3965-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma.
  • AIM: To study the expression of Sonic hedgehog pathway-related molecules, Sonic hedgehog (Shh) and Gli1 in gastric carcinoma.
  • METHODS: Expression of Shh in 56 gastric specimens including non-cancerous gastric tissues, gastric adenocarcinoma, gastric squamous cell carcinoma was detected by RT-PCR, in situ hybridization and immunohistochemistry.
  • Expression of Gli1 was observed by in situ hybridization.
  • RESULTS: The positive rate of Shh and Gli1 expression was 0.0%, 0.0% in non-cancerous gastric tissues while it was 66.7%, 57.8% respectively in gastric adenocarcinoma, and 100%, 100% respectively in gastric squamous cell carcinoma.
  • There was a significant difference between the non-cancerous gastric tissues and gastric carcinoma (P<0.05).
  • Elevated expression of Shh and Gli1 in gastric tubular adenocarcinoma was associated with poorly differentiated tumors while the expression was absent in gastric mucinous adenocarcinoma.
  • CONCLUSION: The elevated expression of Shh and Gli1 in gastric adenocarcinoma and gastric squamous cell carcinoma shows the involvement of activated Shh signaling in the cellular proliferation of gastric carcinogenesis.
  • It suggests Shh signaling gene may be a new and good target gene for gastric tumor diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):172-80 [11175816.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):103-10 [11788837.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9055-67 [11074003.001]
  • (PMID = 16810741.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4087703
  •  go-up   go-down


23. Supriatna Y, Kishimoto T, Uno T, Nagai Y, Ishikura H: Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA. Pathology; 2005 Jun;37(3):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA.
  • AIM: Hepatoid adenocarcinoma, a putative chemosensitive tumour, is defined as a tumour with aberrant hepatocellular differentiation occurring in extrahepatic organs such as the stomach, usually in the gastrointestinal tract.
  • We investigated ALB mRNA to address whether adenocarcinoma with hepatoid morphology, regardless of AFP production, can be diagnosed solely by morphological criteria as a hepatoid adenocarcinoma.
  • METHODS: We performed in situ hybridisation (ISH) and immunohistochemistry (IH) for ALB mRNA on AFP-negative gastric adenocarcinomas with hepatoid morphology.
  • AFP-positive hepatoid adenocarcinomas and AFP-negative conventional gastric adenocarcinomas were also investigated as positive and negative controls, respectively.
  • RESULTS: All three gastric adenocarcinomas with hepatoid morphology with no evidence of AFP production stained positive for ALB mRNA, thus providing evidence of differentiation in the hepatocellular direction.
  • Three of five cases of AFP-positive hepatoid adenocarcinoma of the stomach were positive for ALB mRNA, while 11 cases of AFP-negative conventional gastric adenocarcinoma were negative.
  • CONCLUSION: The present study demonstrates that, irrespective of AFP production, gastric adenocarcinoma with morphological patterns suggestive of hepatoid differentiation should be diagnosed as hepatoid adenocarcinoma with important prognostic implications.
  • [MeSH-major] Adenocarcinoma / pathology. Albumins / biosynthesis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Stomach Neoplasms / pathology. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Diagnosis, Differential. Hepatocytes / pathology. Humans. Immunohistochemistry. In Situ Hybridization. RNA, Messenger / analysis. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175893.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / alpha-Fetoproteins
  •  go-up   go-down


24. Lee CH, Bang SH, Lee SK, Song KY, Lee IC: Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. World J Gastroenterol; 2005 Apr 7;11(13):1937-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ.
  • AIM: To analyze the expression profiles of premalignant and/or preclinical lesions of gastric cancers.
  • METHODS: We analyzed the expression profiles of normal gastric pit, tubular adenoma and carcinoma in situ using microdissected cells from routine gastric biopsies.
  • The differential expression between adenoma and carcinoma in situ was subtle: 50 and 22 genes were up-, and down-regulated in carcinomas at the expected false significance rate of 0.61%, respectively.
  • Differentially expressed genes were grouped according to patterns of the sequential changes for the 'tendency analysis' in the gastric mucosa-adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma in Situ / genetics. Gene Expression Profiling. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800983.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305714
  •  go-up   go-down


25. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer; 2010 Jul;46(11):1949-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trastuzumab in gastric cancer.
  • HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or erbB-2 amplification detected by fluorescent in situ hybridisation, was detected in 22.1% of 3807 patients with advanced gastric and oesophagogastric junction (OGJ) adenocarcinoma screened for eligibility for the phase III ToGA study.
  • The validated scoring system for HER-2 positivity in gastric cancers differs from that recommended for breast cancer due to an increased frequency of incomplete membranous immunoreactivity and heterogeneity of HER-2 expression in gastric cancers.
  • The highest rates of HER-2 over-expression are observed in patients with OGJ rather than gastric tumours and intestinal-type rather than diffuse or mixed histology.
  • The international multicentre randomised phase III ToGA study assessed the addition of trastuzumab to a cisplatin plus fluoropyrimidine (FP) chemotherapy doublet for patients with HER-2-positive advanced gastric or OGJ adenocarcinoma.
  • Trastuzumab plus FP chemotherapy is now the standard of care for patients with advanced gastric and OGJ cancers which over-express HER-2.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542421.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


26. Haveri H, Westerholm-Ormio M, Lindfors K, Mäki M, Savilahti E, Andersson LC, Heikinheimo M: Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol; 2008;8:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Samples of normal and neoplastic gastrointestinal tract from children and adults were subjected to RNA in situ hybridization with 33P labelled probes and immunohistochemistry, using an avidin-biotin immunoperoxidase system.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colonic Neoplasms / genetics. GATA4 Transcription Factor / metabolism. GATA6 Transcription Factor / metabolism. Gastric Mucosa / metabolism. Rectal Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1061-72 [9136933.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1696-710 [16285967.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G297-306 [16603485.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9060-70 [16940177.001]
  • [Cites] Dev Biol. 2002 Jan 1;241(1):34-46 [11784093.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):279-89 [11864602.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):784-9 [11937486.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 7;1576(1-2):198-202 [12031502.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3136-43 [12130579.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 29;1490(3):324-32 [10684977.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):184-8 [10942535.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3476-83 [10999851.001]
  • [Cites] Circ Res. 2000 Oct 13;87(8):699-704 [11029406.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G58-67 [11123198.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1321-57 [11578958.001]
  • [Cites] FEBS Lett. 1997 May 19;408(2):121-3 [9187350.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):G314-24 [9486185.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2901-11 [9566909.001]
  • [Cites] Development. 1998 Dec;125(24):4909-17 [9811575.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Front Biosci. 1999 Mar 15;4:D286-98 [10077541.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(2):71-6 [10190312.001]
  • [Cites] Circ Res. 1999 Apr 2;84(6):647-54 [10189352.001]
  • [Cites] Mol Med. 1999 Jul;5(7):490-501 [10449810.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):952-60 [15541382.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7917-24 [15585625.001]
  • [Cites] J Cell Physiol. 2005 Apr;203(1):15-26 [15389642.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):15-24 [15703995.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] J Pathol. 2002 Aug;197(5):582-8 [12210076.001]
  • [Cites] Mol Pharmacol. 2003 Feb;63(2):368-77 [12527808.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4705-12 [12468531.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8429-39 [14612389.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):408-12 [15144399.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G899-909 [15178553.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1086-99 [14715527.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10876-80 [8248184.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):361-73 [8045339.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1559-67 [9136834.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Gut. 2005 Sep;54(9):1321-31 [16099799.001]
  • (PMID = 18405344.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA6 Transcription Factor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2323380
  •  go-up   go-down


27. Yannopoulos P, Theodoridis P, Manes K: Esophagectomy without thoracotomy: 25 years of experience over 750 patients. Langenbecks Arch Surg; 2009 Jul;394(4):611-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stomach was our esophageal substitute of first choice with the colon and jejunum being acceptable alternatives in patients with prior gastric surgery and those necessitating synchronous gastrectomy for cancer invasion.
  • A gastric tube was used as an esophageal substitute in 624 patients (83.2%), the whole stomach in 70 (9.4%), the colon in 43 (5.73%), and a jejunal loop in 13 (1.73%).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Feb;25(2):196-203 [11338022.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4 [17717440.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5 [11789772.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):162-7 [11918882.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Apr;15(2):197-209 [12838490.001]
  • [Cites] Dis Esophagus. 2003;16(3):243-5 [14641318.001]
  • [Cites] Arch Surg. 2004 Jun;139(6):627-31; discussion 631-3 [15197089.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1170-6; discussion 1170-6 [15464465.001]
  • [Cites] Br J Surg. 1975 Aug;62(8):601-4 [1174797.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Nov;76(5):643-54 [703369.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):419-23; discussion 424 [2635923.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):366-9 [2025191.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):157-63 [7967604.001]
  • [Cites] Chest Surg Clin N Am. 1997 Aug;7(3):601-10; discussion 611-2 [9246405.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Surgery. 1999 Feb;125(2):142-7 [10026746.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Surg Clin North Am. 2005 Jun;85(3):593-610 [15927654.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • (PMID = 19350267.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2687514
  •  go-up   go-down


28. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer; 2009 Feb 10;100(3):487-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.
  • The clinical significance of ERBB2 amplification/overexpression in gastric cancer remains unclear.
  • In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and compared the findings with histopathological characteristics and with disease-specific survival.
  • ERBB2 overexpression (2+ and 3+) and amplification (ratio ERBB2/CEP17 >or= 2) were found in 43 (9.3%) and 38 (8.2%) gastric carcinomas, respectively.
  • ERBB2 amplification was associated with gastric carcinomas of intestinal type (P=0.007) and with an expansive growth pattern (P=0.021).
  • A statistically significant association was found between ERBB2 amplification and worse survival in patients with expansive gastric carcinomas (P=0.011).
  • We conclude that ERBB2 status may have clinical significance in subsets of gastric cancer patients, and that further studies are warranted to evaluate whether patients whose gastric carcinomas present ERBB2 amplification/overexpression may benefit from therapy targeting this surface receptor.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1989 Apr;4(3):362-6 [2565881.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):325-32 [2312109.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Int Surg. 1994 Jan-Mar;79(1):27-32 [8063551.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):537-47 [9247307.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):255-62 [15517369.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1422-7; discussion 1428 [16222448.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Mol Syst Biol. 2006;2:54 [17016520.001]
  • [Cites] Cell Oncol. 2006;28(5-6):283-94 [17167181.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 [6095284.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • (PMID = 19156142.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658544
  •  go-up   go-down


29. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR: Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol; 2010 Nov;41(11):1577-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, trastuzumab was recently shown to be effective in HER-2 positive gastric cancer.
  • To address the potential applicability of anti-HER-2 therapy in colorectal cancer, tissue microarray sections and colorectal resection specimens of 1851 colorectal cancers were analyzed for HER-2 overexpression and amplification using FDA approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Gene Amplification / genetics. Genes, erbB-2 / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Germany / epidemiology. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20656317.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


30. Zhao WH, Wang SF, Ding W, Sheng JM, Ma ZM, Teng LS, Wang M, Wu FS, Luo B: Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. World J Gastroenterol; 2006 Mar 7;12(9):1356-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
  • AIM: To study the apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
  • METHODS: Sixty gastric cancer patients were divided randomly into three groups (20 each group) before operation: group one:5'-DFUR oral administration at the dose of 800-1200 mg/d for 3 - 5 d, group two: 500 mg 5-FU + 200 mg/d CF by venous drip for 3 - 5 d,group three (control group).
  • Fas/FasL,PD-ECGF and PCNA were examined by immunohistochemistry and apoptotic tumor cells were detected by in situ TUNEL method.
  • CONCLUSION: Preoperative oral 5'-DFUR administration may induce apoptosis of gastric carcinoma cells and decrease tumor cell proliferation index,but cannot improve the prognosis of patients with gastric cancer.Down-regulation of FasL and PD-ECGF expression mediated by 5'-DFUR may be one of its anti-cancer mechanisms.Fas expression correlates with the progression of gastric carcinoma and may be an effective prognostic factor.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. Floxuridine / pharmacology. Floxuridine / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4363-7 [10650777.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):31-6 [10963377.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7826-37 [11003676.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Sep;27(10):1521-6 [11015996.001]
  • [Cites] Cell Res. 2000 Sep;10(3):233-42 [11032175.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jan;127(1):20-6 [11206267.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):103-11 [11295293.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1157-62 [11351245.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):222-4 [11778236.001]
  • [Cites] Cell Death Differ. 2002 Apr;9(4):431-8 [11965496.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jan;24(1):4-8 [11977635.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):882-6 [12064013.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):360-3 [12408764.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1628-33 [8608554.001]
  • [Cites] J Surg Oncol. 1997 Jun;65(2):106-10 [9209521.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Oct;24(13):1947-52 [9350241.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Feb;25(3):359-64 [9492829.001]
  • [Cites] Mol Pharmacol. 1998 May;53(5):819-26 [9584207.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Feb;26(3):321-7 [10065095.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1334-42 [10081495.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1145-50 [10098749.001]
  • [Cites] Oncology. 1999 Apr;56(3):215-22 [10202277.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1911-6 [10213500.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2607-12 [12529971.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):115-9 [12469155.001]
  • [Cites] World J Gastroenterol. 2003 Mar;9(3):442-5 [12632493.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):660-4 [12679905.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):717-20 [12679918.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Jan;25(1):66-9 [12678992.001]
  • [Cites] Kongressbd Dtsch Ges Chir Kongr. 2002;119:396-7 [12704896.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1800-7 [12771998.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Aug;32(4):347-9 [14514381.001]
  • [Cites] Surg Today. 2003;33(11):847-53 [14605957.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):348-51 [14760755.001]
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):484-90 [14966903.001]
  • [Cites] World J Gastroenterol. 2004 Mar 15;10(6):804-8 [15040021.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jan;26(1):4-9 [15059341.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1233-9 [15138561.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2174-8 [15259060.001]
  • [Cites] World J Gastroenterol. 2004 Oct 1;10(19):2911-5 [15334700.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1501-6 [1893349.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):509-16 [7676692.001]
  • (PMID = 16552801.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Apoptosis Regulatory Proteins; 0 / FAIM protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Necrosis Factors; 039LU44I5M / Floxuridine; EC 2.4.2.4 / Thymidine Phosphorylase; V1JK16Y2JP / doxifluridine
  • [Other-IDs] NLM/ PMC4124310
  •  go-up   go-down


31. Bonde P, Gao D, Chen L, Miyashita T, Montgomery E, Harmon JW, Wei C: Duodenal reflux leads to down regulation of DNA mismatch repair pathway in an animal model of esophageal cancer. Ann Thorac Surg; 2007 Feb;83(2):433-40; discussion 440
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the effect of reflux, either alone or in combination with the human dietary mutagen methyl-n-amyl nitrosamine (MNAN), on DNA damage in adenocarcinoma and squamous cell cancer of the esophagus in a rat model.
  • METHODS: Reflux was promoted in male Sprague-Dawley rats by duodenoesophageal anastomosis (8 weeks) without gastric bypass.
  • RESULTS: Tumors (adenocarcinoma) developed in 15 (50%) of 30 animals with reflux alone; this increased to 26 (86.6%) of 30 when reflux was combined with MNAN treatment, with tumor histology consistent with adenosquamous and squamous cell cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. DNA Mismatch Repair. Down-Regulation. Duodenogastric Reflux / complications. Duodenogastric Reflux / genetics. Esophageal Neoplasms / etiology
  • [MeSH-minor] Animals. Apoptosis. Carcinogens. Caspases / metabolism. Cytochromes c / metabolism. DNA Damage. DNA Repair Enzymes / metabolism. Guanosine / analogs & derivatives. Guanosine / metabolism. In Situ Nick-End Labeling. Male. Nitrosamines. Rats. Rats, Sprague-Dawley. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257966.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 12133JR80S / Guanosine; 13256-07-0 / N-amyl-N-methylnitrosamine; 3868-31-3 / 8-hydroxyguanosine; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


32. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE, Tannapfel A: Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut; 2007 Aug;56(8):1047-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.
  • AIMS: This study was performed to elucidate the role of SOCS-1 and SOCS-3 in Barrett's adenocarcinoma and its precursor lesions.
  • METHODS: DNA of specimens from 19 Barrett's adenocarcinomas, 56 Barrett's intraepithelial neoplasias (n = 29 low grade and n = 27 high grade), 30 Barrett's mucosa without neoplasia, 20 samples of normal squamous and gastric epithelium and four cell lines were studied using methylation specific PCR for the SOCS-1 and SOCS-3 promoter following microdissection.
  • RESULTS: In normal squamous epithelium and normal gastric mucosa, neither SOCS-3 nor SOCS-1 methylation was observed.
  • CONCLUSIONS: These data indicate that promoter methylation and subsequent transcript downregulation of SOCS-3 transcripts and, to a much lesser extent, SOCS-1 are involved in the multistep carcinogenesis of Barrett's adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Suppressor of Cytokine Signaling Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma, Squamous Cell / genetics. Cell Line, Tumor. CpG Islands / genetics. DNA, Neoplasm / genetics. Humans. Methylation. Neoplasm Proteins / genetics. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics


33. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
  • We wanted to investigate the frequency and clinical significance of HER-2/neu amplification in gastric carcinoma.
  • PATIENTS AND METHODS: The frequency of HER-2/neu and Topoisomerase IIalpha gene amplification was studied in adenocarcinomas of the stomach (n=131) and the gastroesophageal junction (n=100) by chromogenic in situ hybridization (CISH).
  • Sensitivity of a gastric cancer cell line N87 with HER-2/neu amplification to trastuzumab was studied by a cell viability assay and compared with that of a HER-2 amplified breast cancer cell line SKBR-3.
  • RESULTS: HER-2/neu amplification was present in 16 (12.2%) of the 131 gastric and in 24 (24.0%) of the 100 gastroesophageal adenocarcinomas.
  • Co-amplification of Topoisomerase IIalpha was present in the majority of gastric (63%) and esophagogastric junction cancers (68%) with HER-2/neu amplification.
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.
  • HER-2/neu targeting antibody trastuzumab inhibited the growth of a p185(HER-2/neu) overexpressing gastric and breast carcinoma cell lines (N87 and SKBR-3) with equal efficacy.
  • CONCLUSIONS: HER-2/neu amplification is common in the intestinal type of gastric carcinoma, and it is associated with a poor outcome.


34. Shetty VD, Thrumurthy SG, Pursnani KG, Ward JB, Mughal MM: Angelchik prosthesis with oesophageal adenocarcinoma: our surgical approach. Ann R Coll Surg Engl; 2010 Jul;92(5):W64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angelchik prosthesis with oesophageal adenocarcinoma: our surgical approach.
  • However, a variety of major complications including intractable dysphagia, prosthesis migration and gastric erosion required a quarter of these devices to be removed.
  • Development of adenocarcinoma in patients with Angelchik prosthesis is a rare occurrence.
  • This article describes two patients who developed adenocarcinoma above their prosthesis and whose cardio-oesophagectomy was technically challenging due to the formation of a dense inflammatory capsule around the prosthesis.
  • Our surgical approach to curative oesophageal resection with the Angelchik prosthesis in situ is also discussed.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Prostheses and Implants / adverse effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626966.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch; 2006 Jan;448(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype.
  • In this study expression of claudins 1, 3, 4 and 5 were studied in 118 cases of gastric carcinoma and compared with proliferation, apoptosis and E-cadherin expression.
  • Expression of all these claudins could be seen in gastric carcinoma, most prominently for claudin 4, and least expression was found for claudin 5.
  • All claudins showed significantly more expression in gastric carcinomas of intestinal type.
  • The results show that expression of claudins 1, 3, 4 and 5 is lower in diffuse-type gastric carcinomas.
  • Possibly they play a role in determining the diffuse phenotype and loose cohesion of cells in diffuse type of gastric carcinoma in a similar manner as E-cadherin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Cell Proliferation. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / biosynthesis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Cell Biol. 1992 Apr;117(2):415-25 [1373144.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):875-86 [11912246.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):13-6 [10747082.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):531-6 [12231346.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1620-6 [12459629.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] J Cell Biol. 1988 Oct;107(4):1575-87 [3049625.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):476-87 [12110008.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] J Mol Cell Cardiol. 2005 Feb;38(2):323-32 [15698839.001]
  • (PMID = 16220299.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  •  go-up   go-down


36. Targa AC, César AC, Cury PM, Silva AE: Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy. Genet Mol Res; 2007;6(3):554-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy.
  • Thus, the aim of the present study was to investigate the frequency of apoptotic cells (apoptotic index, AI) by using two different immunohistochemical techniques, TUNEL and anti-activated caspase-3 antibody (CPP32), in gastric dyspepsia [chronic gastritis (CG, N = 34), chronic atrophic gastritis (CAG, N = 11), gastric ulcer (GU, N = 17), and intestinal metaplasia (IM, N = 15)], normal gastric mucosae (NM, N = 8), and gastric adenocarcinoma (GC, N = 12).
  • The relationship was investigated between the AI and Helicobacter pylori infection, diagnosed by PCR, overexpression of p53 protein determined by immunohistochemistry, and aneuploidy by fluorescence in situ hybridization, as performed by our laboratory in previous studies.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Caspase 3 / metabolism. Female. Humans. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985308.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 3.4.22.- / Caspase 3
  •  go-up   go-down


37. De Caro G, Pagano N, Malesci A, Hervoso C, Danese S, Romeo F, Delconte G, Repici A: Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report.
  • A 72-year-old woman underwent gastric endoscopic mucosal resection with a cap-fitted endoscope for an adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / adverse effects. Neoplasm Recurrence, Local / surgery. Stomach Diseases / etiology. Stomach Neoplasms / surgery. Surgical Instruments

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620913.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


38. Costa Guimarães A, Gonçalves Quintana L, Ferreira Leal M, Satomi Takeno S, Pimentel Assumpção P, Moura Lima E, Salim Khayat A, Suchi Chen E, de Arruda Cardoso Smith M, Rodríguez Burbano R: Aneuploidy of chromosome 8 detected by fluorescence in situ hybridisation in ACP01 cell line gastric adenocarcinoma. Clin Exp Med; 2006 Oct;6(3):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 detected by fluorescence in situ hybridisation in ACP01 cell line gastric adenocarcinoma.
  • Gastric cancer is the third most frequent type of neoplasia and the second most important cause of death in the world.
  • ACP01 is the first gastric adenocarcinoma cell line developed in Brazil.
  • To evaluate chromosomal aberrations implicated in gastric carcinogenesis, we analysed three different passages (6th, 12th and 35th) of ACP01 cell line by fluorescence in situ hybridisation using chromosome 8 alpha-satellite probe.
  • Our results confirm that trisomy of chromosome 8 is a common biological phenomenon in adenocarcinoma of stomach and can be used as a gastric mucosa malignancy marker.
  • Although gastric tumours are frequent neoplasias, papers on their cytogenetics are scarce in the literature.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Humans. In Situ Hybridization, Fluorescence. Trisomy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061062.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


39. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet; 2009 Nov;126(5):615-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nature meets nurture: molecular genetics of gastric cancer.
  • The immensity of genes and molecules implicated in gastric carcinogenesis is overwhelming and the relevant importance of some of these molecules is too often unclear.
  • The role of E-cadherin in the nature (genotype) of diffuse gastric cancer is highlighted, and finally the ever growing discipline of SNP analysis (including IL1B) is discussed.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Cadherins / genetics. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Environment. Helicobacter Infections / complications. Helicobacter pylori. Humans. Interleukin-1beta / genetics. Precancerous Conditions / epidemiology. Precancerous Conditions / etiology. Precancerous Conditions / genetics. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Science. 1999 Apr 23;284(5414):651-4 [10213689.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1319-29 [10348815.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2373-9 [10483994.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8492-5 [15574751.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2354-66 [15735748.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1618-23 [17582605.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Am J Gastroenterol. 2007 Sep;102(9):1878-92 [17640324.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2013-8 [17690113.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Gut. 2007 Nov;56(11):1503-11 [17337464.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):832-9 [17568183.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4887-94 [17971584.001]
  • [Cites] J Pathol. 2008 Nov;216(3):295-306 [18788075.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2397-403 [18755583.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):408-19 [18977329.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1704-11 [18941457.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):465-77 [16237216.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10912-20 [16322238.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):643-9 [16247479.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):21-33 [16501831.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):564-72 [16474375.001]
  • [Cites] Mod Pathol. 2006 May;19(5):675-83 [16528374.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1975-84 [16762620.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):246-58 [16831607.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):406-15 [16832408.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1558-66 [16646055.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] Gut. 2006 Nov;55(11):1532-3 [17047103.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2250-7 [16774936.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1643-51 [17071588.001]
  • [Cites] Eur J Cancer Prev. 2008 Jun;17(3):195-200 [18414189.001]
  • [Cites] Mod Pathol. 2008 May;21(5):544-52 [18246045.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2909-17 [18483357.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):685-90 [18311113.001]
  • [Cites] J Hum Genet. 2008;53(6):479-89 [18350251.001]
  • [Cites] JAMA. 2008 May 28;299(20):2423-36 [18505952.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):730-40 [18488030.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):799-809 [18391748.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):925-32 [18440592.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2876-82 [18539967.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2655-63 [18442100.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):490-6 [18396115.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4623-30 [18559507.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] J Med Genet. 1999 Dec;36(12):873-80 [10593993.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):403-11 [10719371.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] BMJ. 2000 Jun 17;320(7250):1642-6 [10856067.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):729-35 [10980112.001]
  • [Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1923-31 [11448905.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1348-53 [11729114.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48693-701 [11668179.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):159-64 [9892201.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1267; author reply 1268 [18395110.001]
  • [Cites] Future Oncol. 2008 Apr;4(2):229-39 [18407736.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):774-80 [18342503.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1443-51 [18319718.001]
  • [Cites] Semin Diagn Pathol. 2008 Nov;25(4):274-87 [19013893.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):58-64 [18755497.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):7047-54 [19029944.001]
  • [Cites] Int J Epidemiol. 2008 Dec;37(6):1316-25 [18641418.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2385-93 [18775915.001]
  • [Cites] Am J Epidemiol. 2008 Dec 15;168(12):1409-15 [18945691.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):434-9 [18821580.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):291-8 [19118057.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S161-6 [19120891.001]
  • [Cites] Oncogene. 2008 Jul 10;27(30):4255-60 [18427545.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):392-7 [18675689.001]
  • [Cites] Future Oncol. 2008 Aug;4(4):553-9 [18684065.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1175-81 [18637055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1997-2001 [18708389.001]
  • [Cites] Hum Pathol. 2008 Sep;39(9):1360-9 [18614201.001]
  • [Cites] J Clin Gastroenterol. 2008 Sep;42(8):910-5 [18645534.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] Cancer. 2008 Sep 1;113(5 Suppl):1225-33 [18720378.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7025-34 [18757416.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):827 [18770893.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2402-8 [18768510.001]
  • [Cites] Helicobacter. 2008 Oct;13 Suppl 1:28-34 [18783519.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):249-55 [18688641.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):593-6 [2847662.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6605-9 [2573419.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):689-96 [11875002.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):331-41 [12044009.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 7;294(2):470-9 [12051735.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G767-77 [12181193.001]
  • [Cites] Nat Med. 2002 Sep;8(9):1011-7 [12195435.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):219-31 [12353264.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1406; author reply 1406-7 [12360507.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):888-91 [12373604.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Histopathology. 2003 Feb;42(2):128-36 [12558744.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1408-19 [12730880.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6643-50 [14583457.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):606-12 [14696128.001]
  • [Cites] Gut. 2004 Feb;53(2):195-200 [14724149.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1976-83 [15188375.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] Oncogene. 1988 Mar;2(3):283-7 [3281095.001]
  • [Cites] Int J Cancer. 1996 Feb 20;69(1):38-43 [8600057.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):382-7 [8775994.001]
  • [Cites] Cancer Lett. 1997 Jan 30;112(2):161-6 [9066723.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Gut. 1998 Feb;42(2):300-3 [9536959.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):410-2 [9708215.001]
  • [Cites] Eur Surg Res. 1989;21(6):313-8 [2633929.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Gut. 1992 Jan;33(1):16-20 [1740271.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5853-5 [8261393.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] Gut. 1993 Aug;34(8):1038-41 [8174949.001]
  • [Cites] Scand J Gastroenterol. 1994 May;29(5):425-9 [8036458.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:177-240 [7715070.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Tumour Biol. 2008;29(6):343-50 [19023234.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):160-5 [18669867.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):236-46 [18996125.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):71-7 [19015200.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Eur J Cancer. 2009 Feb;45(3):461-9 [19081245.001]
  • [Cites] Scand J Gastroenterol. 2009;44(3):339-45 [19031173.001]
  • [Cites] Cancer Sci. 2009 Mar;100(3):413-8 [19154407.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2050-6 [19223545.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):500-5 [19147860.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2677-82 [19170207.001]
  • [Cites] Hum Mol Genet. 2009 May 1;18(9):1545-55 [19168852.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):2995-3002 [19383819.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Jun;21(6):630-5 [19295440.001]
  • [Cites] Hum Pathol. 2009 Jun;40(6):769-77 [19269014.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2137-48 [19269290.001]
  • [Cites] Forum Nutr. 2007;60:91-6 [17684404.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2360-72 [17545690.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1855-61 [17505514.001]
  • [Cites] Gut. 2007 Jul;56(7):1023 [17566037.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] J Pathol. 2006 Dec;210(4):398-404 [16981245.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):936-46 [17128210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2427-34 [17164366.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):60-9 [17200707.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1330-5 [17187359.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):15-28 [17311530.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Nat Med. 2007 Apr;13(4):470-6 [17401375.001]
  • [Cites] Nat Genet. 2007 May;39(5):605-13 [17450141.001]
  • [Cites] Virchows Arch. 2007 May;450(5):519-27 [17429689.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10181-9 [17974958.001]
  • [Cites] Helicobacter. 2007 Nov;12 Suppl 2:39-44 [17991175.001]
  • [Cites] Gut. 2007 Dec;56(12):1665-70 [17698860.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1989-98 [18054570.001]
  • [Cites] Am J Epidemiol. 2008 Jan 1;167(1):7-14 [17971340.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):25-30 [17513507.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):234-43 [18176605.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):244-52 [18176606.001]
  • [Cites] BMC Cancer. 2007;7:206 [17996038.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):110-4 [18206535.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):707-14 [18245470.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):500-10 [18242216.001]
  • [Cites] J Gastroenterol. 2008;43(2):115-23 [18306985.001]
  • [Cites] Am J Clin Pathol. 2008 Apr;129(4):613-21 [18343789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4358-63 [18332421.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Cancer Sci. 2008 May;99(5):836-42 [18294278.001]
  • (PMID = 19657673.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / Interleukin-1beta
  • [Number-of-references] 179
  • [Other-IDs] NLM/ PMC2771140
  •  go-up   go-down


40. Kumashiro Y, Yao T, Aishima S, Hirahashi M, Nishiyama K, Yamada T, Takayanagi R, Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol; 2007 Jun;38(6):857-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype.
  • Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to hepatocellular carcinoma.
  • The lesions contain a tubular adenocarcinoma that seems to develop "hepatoid" features, but the relation between the tubular adenocarcinomatous and the hepatoid components remains unclear.
  • We compared the cellular phenotypes of 23 cases of hepatoid adenocarcinoma of the stomach having tubular adenocarcinomatous components with 69 cases of non-hepatoid adenocarcinoma of the stomach.
  • Afterward, we examined the expression of CDX2 and p53 in the tubular adenocarcinomatous and hepatoid components of hepatoid adenocarcinoma.
  • Both components of hepatoid adenocarcinoma were classified into 4 phenotypic categories according to the immunohistochemical results for CD10, MUC2, MUC5AC, and MUC6.
  • In contrast, no gastric phenotype (MUC5AC+, MUC6+, MUC2-, CD10-) was observed in any of the hepatoid adenocarcinoma components.
  • These findings suggest that hepatoid adenocarcinoma arises from an adenocarcinoma with an intestinal phenotype and that its hepatoid component is in some way related to reduced CDX2 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Homeodomain Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Aged. Albumins / metabolism. Disease Progression. Humans. Immunohistochemistry. In Situ Hybridization. Intestinal Mucosa / pathology. Liver Neoplasms / pathology. Middle Aged. Mucin-2. Mucin-6. Mucins / metabolism. Neprilysin / metabolism. Phenotype. RNA, Messenger / analysis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320150.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC6 protein, human; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / alpha-Fetoproteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


41. Yoshiwara E, Koriyama C, Akiba S, Itoh T, Minakami Y, Chirinos JL, Watanabe J, Takano J, Miyagui J, Hidalgo H, Chacon P, Linares V, Eizuru Y: Epstein-Barr virus-associated gastric carcinoma in Lima, Peru. J Exp Clin Cancer Res; 2005 Mar;24(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated gastric carcinoma in Lima, Peru.
  • We examined 254 gastric carcinomas (GCs) diagnosed in four hospitals in Lima, Peru, and its suburban area during the period between 1994-2001.
  • Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) was identified by the in situ hybridization (ISH) technique to detect EBV-encoded small RNA (EBER) in gastric tissue.
  • EBVaGCs, where EBER ISH staining was observed in all carcinoma cells, accounted for 3.9% (10/254) of gastric adenocarcinomas, the lowest frequency ever reported in Latin American countries.
  • Other clinicopathological features of EBVaGC in Peru were similar to those found in literature: EBVaGC showed no age dependence, a predominance in the non-antrum part of the stomach, and high frequencies in histological subtypes of moderately differentiated tubular adenocarcinoma and solid poorly differentiated adenocarcinoma.
  • There was a case of well-differentiated adenocarcinoma showing a partial EBER-1-positive staining.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943031.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


42. Kimura M, Tsuda H, Morita D, Shinto E, Tanimoto T, Ichikura T, Mochizuki H, Matsubara O: Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol; 2005 Jun;35(6):324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
  • METHODS: Endoscopic biopsy specimens and specimens of whole representative cut surfaces of corresponding surgically resected tumors were obtained from 14 patients with gastric carcinoma, and immunohistochemistry and fluorescence in situ hybridization were then performed to determine the protein expression and gene amplification profiles, respectively, of EGFR and c-erbB-2 in these biopsy and surgical specimens.
  • RESULTS: Among the eight endoscopic biopsy specimens obtained from three gastric carcinomas in which EGFR protein overexpression and gene amplification were judged to be positive in the corresponding surgically resected tissue specimens, EGFR overexpression was detected in three specimens (38%), but EGFR amplification was not detected (0%).
  • Among the 19 endoscopic biopsy specimens obtained from five gastric carcinomas in which c-erbB-2 protein overexpression and gene amplification were judged to be positive in the corresponding surgically resected tissue specimens, c-erbB-2 overexpression and amplification (c-erbB-2/CEP17 ratio) were detected in 14 (74%) and 16 (84%) specimens, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Gastrectomy. Gastroscopy. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928192.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


43. Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Höcker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol; 2006 Jan 10;24(2):228-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
  • Nodal dissemination of gastric adenocarcinomas critically determines clinical outcome and therapeutic options of affected patients.
  • Therefore, we analyzed expression and prognostic significance of VEGF-D along with VEGF-C, and VEGFR-3 in gastric adenocarcinomas.
  • MATERIALS AND METHODS: VEGF-C, VEGF-D, and VEGFR-3 were analyzed in 91 R(0)-resected primary gastric adenocarcinomas, corresponding noncancerous gastric mucosa, and lymph node metastases employing immunohistochemistry and/or in situ hybridization.
  • RESULTS: VEGF-D and VEGF-C were detected in 67.0% and 50.5% of gastric cancers, respectively.
  • Healthy gastric mucosa was negative for VEGF-C and in 12.5% positive for VEGF-D.
  • In lymph node-positive gastric cancers, presence of VEGF-D/VEGFR-3 was associated with poor survival, whereas absence of VEGF-D/VEGFR-3 defined a subgroup of patients with clearly favorable prognosis.
  • CONCLUSION: VEGF-D and VEGFR-3 are novel independent prognostic marker molecules aiding to identify patients with poor prognosis after curative resection of gastric adenocarcinomas.
  • Combined analysis of the VEGF-C/VEGF-D/VEGFR-3 system can be useful to identify patients with unfavorable clinical outcome and thereby may help to refine therapeutic decisions in gastric cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / mortality. Stomach Neoplasms / chemistry. Stomach Neoplasms / mortality. Vascular Endothelial Growth Factor D / analysis. Vascular Endothelial Growth Factor Receptor-3 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


44. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis; 2005 Oct;26(10):1698-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas.
  • Here, we report our findings that the elevated expression of hedgehog target genes human patched gene 1 (PTCH1) or Gli1 occurs in 63 of the 99 primary gastric cancers.
  • Treatment of gastric cancer cells with KAAD-cyclopamine, a hedgehog signaling inhibitor, decreases expression of Gli1 and PTCH1, resulting in cell growth inhibition and apoptosis.
  • Thus, our analysis of in vivo tissues indicates that the hedgehog pathway is frequently activated in advanced gastric adenocarcinomas; our in vitro studies suggest that hedgehog signaling contributes to gastric cancer cell growth.
  • These data predict that targeted inhibition of the hedgehog pathway may be effective in the prevention and treatment of advanced gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. Trans-Activators / genetics
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Hedgehog Proteins. Humans. In Situ Hybridization. Male. Neoplasm Staging. Oncogene Proteins / genetics. Receptors, Cell Surface / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905200.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


45. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology; 2009 Sep;137(3):824-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location.
  • BACKGROUND & AIMS: Epstein-Barr virus (EBV) has been causally associated with cancer; some gastric carcinomas have a monoclonal EBV genome in every cancer cell, indicating that they arose from a single infected progenitor cell.
  • However, the proportion of EBV-positive gastric carcinomas is uncertain, and the etiologic significance is unknown.
  • METHODS: We conducted a meta-analysis of 70 studies including 15,952 cases of gastric cancer assessed by in situ hybridization for EBV-encoded small RNA.
  • RESULTS: The pooled prevalence estimate of EBV positivity was 8.7% (95% confidence interval [CI]: 7.5%-10.0%) overall, with a 2-fold difference by sex: 11.1% (95% CI: 8.7%-14.1%) of gastric cancer cases in males vs 5.2% (95% CI: 3.6%-7.4%) of cases in females.
  • Tumors arising in the gastric cardia (13.6%) or corpus (13.1%) were more than twice as likely to be EBV-positive as those in the antrum (5.2%; P < .01 for both comparisons).
  • EBV prevalence was 4 times higher (35.1%) for tumors in postsurgical gastric stump/remnants.
  • CONCLUSIONS: EBV-positive gastric cancers greatly differ from other gastric carcinomas based on sex, anatomic subsite, and surgically disrupted anatomy, indicating that it is a distinct etiologic entity.
  • Epidemiologic studies comparing EBV-positive and -negative gastric cancers are warranted to investigate EBV's role in gastric carcinogenesis.
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma / virology. Cardia / virology. Epstein-Barr Virus Infections / complications. Female. Gastric Stump. Humans. Male. Pyloric Antrum / virology. Sex Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):379-85 [16270524.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):547-53 [16471317.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1842-8 [16609989.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):905-11 [16772418.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1270-1 [16980313.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):354-63 [10989635.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):69-75 [11263593.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):911-7 [11572757.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):702-4 [11875729.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):825-9 [12190097.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):384-9 [12226826.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2008-9 [12242430.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] J Pathol. 2003 Apr;199(4):447-52 [12635135.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):478-80 [12683879.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):641-51 [12861059.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1093-8 [15492798.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] IARC Sci Publ. 1978;(20):167-89 [215514.001]
  • [Cites] Arch Surg. 1982 Mar;117(3):294-7 [7065870.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5455-9 [8390666.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):73-81 [8041121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1158-63 [7943537.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):695-8 [7962618.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):174-81 [8607441.001]
  • [Cites] Histopathology. 1996 Feb;28(2):121-7 [8834519.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Jpn J Cancer Res. 1997 Mar;88(3):262-6 [9140110.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):360-7 [9211523.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:47-373 [9612712.001]
  • [Cites] Oral Oncol. 1998 Jan;34(1):15-23 [9659515.001]
  • [Cites] Pathol Res Pract. 1998;194(10):705-11 [9820867.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):662-6 [9930069.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1582-6 [10364028.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1214-9 [10370694.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15730-5 [15498875.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gut. 2007 Dec;56(12):1671-7 [17627962.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):884-91 [18240345.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):195-201 [18271915.001]
  • [Cites] Aging Clin Exp Res. 2008 Apr;20(2):91-102 [18431075.001]
  • [Cites] Hepatogastroenterology. 2008 Jan-Feb;55(81):41-5 [18507075.001]
  • [Cites] Scand J Gastroenterol. 2008;43(6):669-74 [18569983.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4347-51 [18666324.001]
  • [Cites] Int J Epidemiol. 2008 Oct;37(5):1158-60 [18832388.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Gastroenterol. 2005 Jun;40(6):570-7 [16007390.001]
  • [ErratumIn] Gastroenterology. 2011 Mar;140(3):1109
  • (PMID = 19445939.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS424076; NLM/ PMC3513767
  •  go-up   go-down


46. Grundmann RT, Hölscher AH, Bembenek A, Bollschweiler E, Drognitz O, Feuerbach S, Gastinger I, Hermanek P, Hopt UT, Hünerbein M, Illerhaus G, Junginger T, Kraus M, Meining A, Merkel S, Meyer HJ, Mönig SP, Piso P, Roder J, Rödel C, Tannapfel A, Wittekind C, Woeste G: [Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir; 2009 Aug;134(4):362-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of and therapy for gastric cancer--work-flow].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms--Workflow.
  • AIM: This review comments on the diagnosis and treatment of gastric cancer in the classical meaning--excluding adenocarcinoma of the -oesophagogastric junction.
  • In all other cases total gastrectomy or distal subtotal gastric resection are indicated, the latter in cases of tumours located in the distal two-thirds of the stomach.
  • [MeSH-minor] Biopsy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Gastroscopy. Humans. Laparoscopy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Palliative Care. Perioperative Care. Peritoneal Lavage. Prognosis. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart.New York.
  • (PMID = 19688686.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 109
  •  go-up   go-down


47. Jang CS, Park DK, Kwon KA, Yu SK, Kim YK: Pneumothorax as a complication of ESD. Endoscopy; 2007 Feb;39 Suppl 1:E59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Cardia / surgery. Gastric Mucosa / surgery. Gastroscopy / adverse effects. Pneumothorax / etiology. Postoperative Complications / etiology. Stomach Neoplasms / surgery


48. Ferrasi AC, Pinheiro NA, Rabenhorst SH, Caballero OL, Rodrigues MA, de Carvalho F, Leite CV, Ferreira MV, Barros MA, Pardini MI: Helicobacter pylori and EBV in gastric carcinomas: methylation status and microsatellite instability. World J Gastroenterol; 2010 Jan 21;16(3):312-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori and EBV in gastric carcinomas: methylation status and microsatellite instability.
  • AIM: To verify the methylation status of CDH1, DAPK, COX2, hMLH1 and CDKN2A genes and to evaluate their association with Helicobacter pylori (H. pylori)-cagA(+) and Epstein Barr virus (EBV) infections in gastric adenocarcinomas.
  • METHODS: Methylation-specific PCR (MSP) assay was performed in 89 primary gastric carcinomas (intestinal and diffuse types).
  • The presence of EBV was assessed by in situ hybridization.
  • Intestinal and diffuse adenocarcinomas showed different methylation profiles and there was an association between methylation of E-CDH1 and H. pylori-cagA(+) in the intestinal adenocarcinoma type.
  • CONCLUSION: We found a strong association between CDH1 methylation and H. pylori-cagA(+) in intestinal-type gastric cancer, association of MSI and better prognosis and an heterogeneous COX-2 overexpression.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Helicobacter pylori / isolation & purification. Herpesvirus 4, Human / isolation & purification. Microsatellite Instability. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):200-3 [10861474.001]
  • [Cites] Braz J Med Biol Res. 2004 Nov;37(11):1707-12 [15517087.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2399-403 [11289104.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2847-51 [11306456.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Mol Pharmacol. 2004 Dec;66(6):1465-77 [15456896.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] World J Gastroenterol. 2005 Jul 28;11(28):4363-6 [16038035.001]
  • [Cites] Gastric Cancer. 2005;8(4):238-44 [16328598.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii97-102 [16760303.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1557-67 [16949912.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1361-71 [17509026.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):379-87 [18199531.001]
  • [Cites] Dig Dis Sci. 2009 Jan;54(1):103-10 [18465229.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):2995-3002 [19383819.001]
  • [Cites] PLoS Genet. 2009 Aug;5(8):e1000602 [19680444.001]
  • [Cites] Arch Surg. 2009 Aug;144(8):722-7 [19687375.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):911-7 [11572757.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):272-7 [11774276.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):246-9 [12532440.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):807-13 [12632072.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4128-33 [12821947.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):491-500 [12920592.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1705-13 [14630673.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] IARC Sci Publ. 2004;(157):301-10 [15055303.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):915-22 [15133479.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):273-8 [15352040.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] J Clin Microbiol. 1995 Oct;33(10):2752-6 [8567918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):300-3 [9000572.001]
  • [Cites] Trends Genet. 1997 Nov;13(11):444-9 [9385841.001]
  • [Cites] J Clin Gastroenterol. 1997 Dec;25(4):646-9 [9451680.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1749-54 [9676851.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4347-53 [10361133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1511-6 [10995806.001]
  • (PMID = 20082476.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / CDH1 protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC2807951
  •  go-up   go-down


49. Papaziogas B, Koutelidakis I, Tsiaousis P, Panagiotopoulou K, Paraskevas G, Argiriadou H, Atmatzidis S, Atmatzidis K: Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report. Cases J; 2008;1(1):249
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we describe the first case of endoepithelial carcinoma arising in a gastric heterotopic pancreas of a 56-year old woman in Greece.
  • Esophagogastroduodenoscopy revealed an ulcerated lesion in the gastric antrum, biopsies of which showed intense epithelial dysplasia with incipient malignant degeneration.
  • The pathology report of the distal gastrectomy specimen demonstrated a 2 cm in diameter ulcerative mass in the gastric antrum.
  • Microscopically, an endoepithelial (in situ) carcinoma of the gastric antrum was determined, which in places turned into an microinvasive endomucosal adenocarcinoma.
  • It also incidentally demonstrated heterotopic pancreatic ducts, detected within the mucosa to the muscularis propria of the same region of the stomach, in which an endoepithelial (in situ) carcinoma was evolving.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1995 May;33(5):260-4 [7610694.001]
  • [Cites] Histopathology. 1992 May;20(5):433-5 [1587493.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1289-92 [1812259.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):196-8 [2032610.001]
  • [Cites] Postgrad Med J. 1988 Oct;64(756):801-3 [3255924.001]
  • [Cites] Am J Gastroenterol. 1990 May;85(5):597-601 [2337064.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] J Pediatr Surg. 1977 Aug;12(4):593-9 [894461.001]
  • [Cites] Can J Surg. 1976 Sep;19(5):413-4 [974927.001]
  • [Cites] Arch Surg. 1974 Dec;109(6):762-5 [4420439.001]
  • [Cites] J Korean Med Sci. 2004 Feb;19(1):145-8 [14966359.001]
  • [Cites] Can J Surg. 2001 Dec;44(6):407 [11764870.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):549-54 [11472568.001]
  • [Cites] West J Med. 1981 Jul;135(1):57-62 [7257381.001]
  • (PMID = 18928565.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577107
  •  go-up   go-down


50. Ftériche F, Bouzid T, Makni A, Ksantini R, Bdioui H, Chebbi F, Jouini M, Ammous A, Kacem M, Ben Safta Z: [Gastric adenocarcinoma with lymphoid stroma. About nine cases]. Tunis Med; 2007 Aug;85(8):688-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma with lymphoid stroma. About nine cases].
  • [Transliterated title] L'adénocarcinome gastrique à stroma lymphoïde. A propos de neuf cas.
  • AIM: the purpose of this work is to study the pathological features and the outcome of lymphoid stroma gastric carcinoma and its relation with Epstein-Bar Virus (EBV) and the imortance of the EBV serology in detection of early reccurence.
  • METHODS: between january 1990 and december 2004, 155 patients underwent gastric resection for gastric carcinoma.
  • Nine of them had lymphoid stroma gastric carcinoma.
  • A comprison of survival rate of patients beteween current gastric carcinoma and those with lymphoid stroma gatsric carcinoma was done using the Log Rank test.
  • EBV was detected in all patients by in situ hybridation.
  • CONCLUSION: lymphoid stroma gastric carcinoma is a bulky, local disease.
  • Over all survival was better than survival of current gastric carcinoma, although there was no significance.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254293.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


51. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P: Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol; 2007 Dec;60(12):1358-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gold standard remains in situ EBER detection, but detection of EBNA1 would be an interesting alternative.
  • EBV-positive common gastric adenocarcinomas seem to have a better prognosis than their EBV-negative counterparts and identification of the virus in B cell lymphoproliferations in immunocompromised individuals will guide therapeutic options.
  • [MeSH-minor] Adenocarcinoma / virology. Hematologic Neoplasms / virology. Humans. Immunocompromised Host. Lymphoproliferative Disorders / immunology. Lymphoproliferative Disorders / virology. RNA-Binding Proteins / analysis. Ribosomal Proteins / analysis. Stomach Neoplasms / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] J Pathol. 1993 Jun;170(2):137-43 [8393922.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1044-9 [8214001.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] Virology. 1999 Apr 10;256(2):196-202 [10191184.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 17;93(2):148-50 [11208885.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):783-90 [11259092.001]
  • [Cites] Eur J Dermatol. 2001 May-Jun;11(3):203-8 [11358725.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):721-31 [11395549.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):927-40 [11581315.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1287-92 [11583956.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1111-20 [11688570.001]
  • [Cites] Laryngoscope. 2002 Mar;112(3):482-7 [12148858.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):608-14 [12152159.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4255-60 [12377970.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] Virology. 2003 Feb 15;306(2):236-43 [12642097.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):39-45 [7805038.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1093-8 [7557942.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1300-12 [7573693.001]
  • [Cites] J Pathol. 1995 Oct;177(2):115-22 [7490676.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4531-7 [8639820.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):747-53 [8651355.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):313-24 [8772785.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Cancer Surv. 1997;30:233-48 [9547995.001]
  • [Cites] Eur Respir J. 1998 Jul;12(1):102-6 [9701422.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):59-65 [16330943.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):75-82 [16330945.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):223-9 [16434897.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2782-9 [16385574.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):250-6 [16616072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]
  • [Cites] J Pathol. 2006 Aug;209(4):430-5 [16710842.001]
  • [Cites] J Pathol. 2006 Aug;209(4):427-9 [16906594.001]
  • [Cites] J Clin Exp Hematop. 2006 Mar;46(1):1-4 [17058802.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1312-6 [17076712.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):4-14 [17064952.001]
  • [Cites] J Virol. 2007 Jun;81(11):5484-96 [17376918.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):887-95 [17509986.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):588-94 [17417777.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):44-53 [17555446.001]
  • [Cites] J Virol. 2007 Jul;81(13):7249-68 [17376908.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1077-88 [17592275.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] J Oral Pathol Med. 2004 Jan;33(1):30-6 [14675138.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] Uirusu. 2003 Dec;53(2):211-6 [15071960.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):455-9 [15116326.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Can Med Assoc J. 1970 Dec 19;103(13):1362-5 [4923839.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • (PMID = 17873116.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  • [Number-of-references] 72
  • [Other-IDs] NLM/ PMC2095566
  •  go-up   go-down


52. Lo YC, Yang YC, Wu IC, Kuo FC, Liu CM, Wang HW, Kuo CH, Wu JY, Wu DC: Capsaicin-induced cell death in a human gastric adenocarcinoma cell line. World J Gastroenterol; 2005 Oct 28;11(40):6254-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capsaicin-induced cell death in a human gastric adenocarcinoma cell line.
  • Cell death induced by the binding of capsaicin was examined in a human gastric adenocarcinoma cell line (AGS cells).
  • Therefore, capsaicin might induce protection from gastric cancer.
  • [MeSH-major] Adenocarcinoma. Capsaicin / pharmacology. Cell Death / drug effects. Stomach Neoplasms
  • [MeSH-minor] Cell Line, Tumor. DNA Fragmentation. Humans. In Situ Nick-End Labeling. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPSAICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419151.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; S07O44R1ZM / Capsaicin
  • [Other-IDs] NLM/ PMC4320326
  •  go-up   go-down


53. Yilmaz O, Demiray E: Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. World J Gastroenterol; 2007 Feb 7;13(5):671-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy.
  • H pylori is etiologically associated with gastritis, gastric and duodenal ulcers, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma.
  • Fluorescence in situ hybridization (FISH) method on paraffin embedded tissue is a rapid, accurate and cost-effective method for the detection of H pylori infection and to determine clarithromycin resistance within three hours according to the gold standards as a non-culture method.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Clarithromycin / therapeutic use. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):830-8 [10655393.001]
  • [Cites] Helicobacter. 2005 Aug;10(4):353-9 [16104952.001]
  • [Cites] Gut. 2000 May;46(5):608-14 [10764702.001]
  • [Cites] Curr Pharm Des. 2000 Oct;6(15):1537-44 [10974150.001]
  • [Cites] J Clin Microbiol. 2000 Oct;38(10):3710-4 [11015388.001]
  • [Cites] J Clin Microbiol. 2001 Jan;39(1):304-8 [11136788.001]
  • [Cites] J Med Microbiol. 2001 Mar;50(3):215-22 [11232765.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1217-20 [11283030.001]
  • [Cites] Antimicrob Agents Chemother. 2001 May;45(5):1500-4 [11302817.001]
  • [Cites] J Clin Microbiol. 2001 Nov;39(11):4142-4 [11682543.001]
  • [Cites] J Med Microbiol. 2001 Dec;50(12):1021-9 [11761185.001]
  • [Cites] Drug Resist Updat. 2001 Jun;4(3):178-86 [11768331.001]
  • [Cites] Gut. 2002 Mar;50(3):285-9 [11839700.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Dec;16(12):2073-9 [12452940.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):397-402 [12517879.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):813-5 [12574289.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4573-7 [14532184.001]
  • [Cites] BMC Microbiol. 2004 Jan 27;4:5 [14969595.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):684-9 [15044917.001]
  • [Cites] Gut. 2004 Sep;53(9):1374-84 [15306603.001]
  • [Cites] J Clin Microbiol. 2004 Oct;42(10):4512-8 [15472302.001]
  • [Cites] J Clin Microbiol. 1992 Jan;30(1):192-200 [1734052.001]
  • [Cites] FEMS Microbiol Lett. 1996 Aug 15;142(1):37-42 [8759787.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):477-80 [8834903.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):1044-5 [9041272.001]
  • [Cites] Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1:43-53 [9146790.001]
  • [Cites] Clin Microbiol Rev. 1997 Oct;10(4):720-41 [9336670.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Dec;41(12):2621-8 [9420030.001]
  • [Cites] J Korean Med Sci. 1999 Feb;14(1):15-20 [10102518.001]
  • [Cites] J Clin Microbiol. 1999 Jul;37(7):2236-40 [10364591.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3746-8 [10523591.001]
  • [Cites] APMIS. 2004 Nov-Dec;112(11-12):886-97 [15688524.001]
  • [Cites] J Clin Microbiol. 2005 Jul;43(7):3494-6 [16000488.001]
  • [Cites] J Med Microbiol. 2000 Apr;49(4):343-7 [10755628.001]
  • (PMID = 17278188.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; H1250JIK0A / Clarithromycin
  • [Number-of-references] 49
  • [Other-IDs] NLM/ PMC4065998
  •  go-up   go-down


54. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol; 2006 Oct 20;24(30):4922-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
  • PURPOSE: A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia and distal gastric adenocarcinomas.
  • PATIENTS AND METHODS: Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg/d orally.
  • No somatic mutations of the EGFR exons 18, 19, or 21 were detected and there was no gross amplification of EGFR by fluorescence in situ hybridization.
  • CONCLUSION: Erlotinib is active in patients with GEJ adenocarcinomas, but appears inactive in gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):910; author reply 911 [17327617.001]
  • [ErratumIn] J Clin Oncol. 2007 Jun 1;25(16):2334
  • (PMID = 17050876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


55. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4309-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
  • PURPOSE: Epidermal growth factor receptor (EGFR) is highly expressed in some gastric cancers and is implicated in cancer cell growth and proliferation.
  • The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
  • METHODS: Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d).
  • CONCLUSION: Gefitinib reached the tumors at concentrations sufficient to inhibit EGFR activation in advanced gastric carcinoma patients, although this did not translate into clinical benefit.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]
  • (PMID = 16963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


56. Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol; 2010 Dec;41(12):1742-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
  • This study was conducted to investigate the roles of ribonucleotide reductase M2 subunit in gastric cancer.
  • In normal gastric mucosa, ribonucleotide reductase M2 subunit expression was restricted to the neck regions of gastric pits and no expression was observed in the surface epithelium.
  • Among 112 gastric cancer tissues, ribonucleotide reductase M2 subunit overexpression (≥10% cancer cells stained) was observed in 72 cases (64.3%).
  • Suppression of ribonucleotide reductase M2 subunit synthesis, using small interfering RNA, inhibited the growth of 3 gastric cancer cell lines, MKN-1, MKN-7, and SNU-719.
  • Our data suggest that ribonucleotide reductase M2 subunit overexpression could be associated with the gastric cancer progression and that suppression of its function is a potential therapeutic strategy in gastric cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Enzyme Inhibitors / pharmacology. Ribonucleoside Diphosphate Reductase / antagonists & inhibitors. Ribonucleoside Diphosphate Reductase / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Epstein-Barr Virus Infections. Female. Gastric Mucosa. Gene Silencing. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. RNA, Small Interfering / genetics. Tissue Array Analysis. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20825972.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / RNA, Small Interfering; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase
  •  go-up   go-down


57. Yang Q, Ye ZY, Zhang JX, Tao HQ, Li SG, Zhao ZS: Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken); 2010 Dec;293(12):2012-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis.
  • To investigate matrix metalloproteinase-9 (MMP-9) mRNA and vascular endothelial growth factor (VEGF) protein expression in gastric carcinoma and its correlation with microvascular density, growth-pattern, invasion, metastasis, and prognosis.
  • In situ hybridization of MMP-9 mRNA and immunohistochemistry of VEGF and CD34 proteins were performed on surgical specimens of gastric cancers from 118 patients compared with 20 nonmalignant gastric mucosae.
  • The positive rate of MMP-9 in noncancerous gastric mucosae was significantly lower than that of gastric cancer tissue (60.17%, P < 0.01).
  • MMP-9 and VEGF expression is associated with enhanced tumor angiogenesis and may play crucial roles in the invasion and metastasis of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 9 / metabolism. Stomach Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / genetics. Antigens, CD34 / metabolism. Case-Control Studies. Chi-Square Distribution. Female. Gastric Mucosa / metabolism. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Prognosis. RNA, Messenger / analysis. Reference Values

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21089052.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


58. Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N: Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body. Dig Surg; 2008;25(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 10 patients with intraductal papillary mucinous neoplasms, 3 patients had minimally invasive adenocarcinoma, and 3 had adenocarcinoma in situ.
  • A medial pancreatectomy was converted to a distal pancreatectomy in 1 patient with adenocarcinoma in situ.
  • Postoperative complications occurred in 6 patients (43%): 5 had pancreatic fistulas and 1 had a gastric ulcer.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Islet Cell / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292661.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


59. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases.
  • We report here two cases of inflammatory breast metastases from gastric or ovarian cancer.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


60. Wu IC, Wu MT, Chen YK, Hsu MC, Chou SH, Lee CH, Shiea JT, Wu IL, Huang CT, Wu DC: Apoptotic effect of Helicobacter pylori on oesophageal squamous-cell carcinoma cells in vitro. Eur J Clin Invest; 2008 Oct;38(10):760-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: One ESCC (CE 81T/VGH) cell line was co-cultured with Hp, using one gastric adenocarcinoma (AGS) cell line as the control.
  • [MeSH-minor] Annexin A5 / analysis. Apoptosis. Biomarkers / analysis. Caspase 3 / analysis. Cell Line, Tumor. Flow Cytometry. Helicobacter Infections / pathology. Humans. In Situ Nick-End Labeling


61. Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S, Takano Y: The role of Reg IV gene and its encoding product in gastric carcinogenesis. Hum Pathol; 2010 Jan;41(1):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Reg IV gene and its encoding product in gastric carcinogenesis.
  • To clarify the role of Reg IV in gastric carcinogenesis and subsequent progression, we examined its expression by immunohistochemistry and in situ hybridization on tissue microarray containing gastric carcinoma, adjacent nonneoplastic mucosa, adenoma, intestinal metaplasia, or gastritis.
  • Gastric carcinoma cell lines (MKN28, AGS, MKN45, KATO-III, and HGC-27) were studied for Reg IV expression by Western blot and reverse transcriptase-polymerase chain reaction followed by sequencing.
  • Frozen samples of gastric carcinoma and adjacent nonneoplastic mucosa were subjected to Western blot, and patient serum, to enzyme-linked immunosorbent assay for Reg IV.
  • Gastric carcinoma cell lines showed different levels of Reg IV mRNA and its encoding protein.
  • Elevated serum Reg IV level in gastric carcinoma patients was detected in comparison with that in health individuals (P < .05).
  • Our study indicated that Reg IV expression experienced up-regulation in gastric intestinal metaplasia and adenoma and then down-regulation with malignant transformation of gastric epithelial cells.
  • It was suggested that Reg IV expression should be considered as a good biomarker for gastric precancerous lesions and was especially related to the histogenic pathway of signet ring cell carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA, Neoplasm / analysis. Female. Gastric Mucosa / metabolism. Gastritis / genetics. Gastritis / metabolism. Gastritis / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Precancerous Conditions. Sequence Analysis, DNA. Tissue Array Analysis


62. Leteurtre E, Zerimech F, Piessen G, Wacrenier A, Leroy X, Copin MC, Mariette C, Aubert JP, Porchet N, Buisine MP: Relationships between mucinous gastric carcinoma, MUC2 expression and survival. World J Gastroenterol; 2006 Jun 7;12(21):3324-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships between mucinous gastric carcinoma, MUC2 expression and survival.
  • AIM: To investigate the expression of the four secreted gel-forming mucins (MUC2, MUC5AC, MUC5B and MUC6) in a series of gastric carcinomas, classified according Lauren's, Mulligan's, WHO and Goseki's classifications, with special attention to all the different components (major and minor) present in tumors and to follow up clinical data.
  • METHODS: Expression of MUC2, MUC5AC, MUC5B and MUC6 was investigated using immunohistochemistry and in situ hybridization.
  • RESULTS: Expression of secreted gel-forming mucins in gastric carcinoma was particularly complex, each mucin being not restricted to any histopathological type even considering all components (major and minor) present in a given tumor.
  • CONCLUSION: Complexity of mucin gene expression patterns in gastric cancer may reflect a precise state of differentiation at the cell level not recognized in used morphologic classification systems.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Mucins / genetics. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2002 Mar;440(3):304-10 [11889602.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):958-72 [12218214.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):887-93 [12417511.001]
  • [Cites] Med Sci (Paris). 2004 May;20(5):569-74 [15190477.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):954-64 [15309883.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Pathol Annu. 1972;7:349-415 [4557936.001]
  • [Cites] Gut. 1992 May;33(5):606-12 [1377153.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Biochem Soc Trans. 1995 Nov;23(4):845-51 [8654851.001]
  • [Cites] J Pathol. 1997 Aug;182(4):385-91 [9306958.001]
  • [Cites] Biochem J. 1998 Sep 15;334 ( Pt 3):685-93 [9729478.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Feb;20(2):209-18 [9922211.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] J Pathol. 1998 Dec;186(4):398-405 [10209489.001]
  • [Cites] Cancer. 1999 May 15;85(10):2114-8 [10326687.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3182-8 [15929165.001]
  • [Cites] Virchows Arch. 2002 May;440(5):505-11 [12021925.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] J Pathol. 2000 Mar;190(4):437-43 [10699992.001]
  • [Cites] J Histochem Cytochem. 2000 Dec;48(12):1657-66 [11101634.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15386-96 [11278696.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1321-57 [11578958.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1192-206 [11578969.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Trends Biochem Sci. 2002 Mar;27(3):126-31 [11893509.001]
  • (PMID = 16733847.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  • [Other-IDs] NLM/ PMC4087862
  •  go-up   go-down


63. Curiel-Valdés Jde J, Sánchez-Martínez F, Valdez-Carrillo C, Olvera-Gil H, Zavala E: [Severe gastric dysplasia with intramucosal carcinoma in a 16-year-old male]. Cir Cir; 2007 Jan-Feb;75(1):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe gastric dysplasia with intramucosal carcinoma in a 16-year-old male].
  • Gastric dysplasia is a rare adult condition affecting a small area near polyps, ulcers or is an inflammatory process.
  • Adenocarcinoma develops in severe gastric dysplasia, and this process may take 1 year.
  • We report a severe dysplasia in a 16-year-old male with no clinical history of gastric disease with acute and severe upper gastrointestinal bleeding that lowered hemoglobin levels to 2.8 g/dL.
  • No similar cases of severe dysplasia with carcinoma in situ are reported in the literature.
  • [MeSH-minor] Adolescent. Gastric Mucosa / pathology. Humans. Male. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470326.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


64. Abdirad A, Ghaderi-Sohi S, Shuyama K, Koriyama C, Nadimi-Barforoosh H, Emami S, Mosavi-Jarrahi A, Nahvijou A, Akiba S: Epstein-Barr virus associated gastric carcinoma: a report from Iran in the last four decades. Diagn Pathol; 2007;2:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated gastric carcinoma: a report from Iran in the last four decades.
  • BACKGROUND: Epstein-Barr virus has been proved to be associated with many of the human malignancy including gastric carcinoma, one of the most important human malignancies in the world.
  • There has been no study about the presence of EBV in gastric adenocarcinoma in Iran.
  • METHODS: We examined the presence of EBV in 273 formalin fixed paraffin-embedded cases of gastric carcinoma from Cancer institute of Tehran University, from 1969 to 2004.
  • In situ hybridization of EBV-encoded small RNA-1 (EBER-1) was conducted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Nov 1;88(9):3491-501 [8896415.001]
  • [Cites] J Med Virol. 1996 Dec;50(4):314-21 [8950688.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):155-8 [9139835.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2899-916 [9205097.001]
  • [Cites] Blood. 1997 Jul 1;90(1):323-30 [9207468.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):72-6 [9212226.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Immunity. 1998 Sep;9(3):395-404 [9768759.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):747-9 [10328099.001]
  • [Cites] Mod Pathol. 1999 Sep;12(9):873-8 [10496595.001]
  • [Cites] J Virol. 1999 Dec;73(12):9827-31 [10559294.001]
  • [Cites] Pathol Res Pract. 2001;197(6):395-400 [11432666.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):911-7 [11572757.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):702-4 [11875729.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):384-9 [12226826.001]
  • [Cites] Int J Cancer. 2002 Oct 20;101(6):560-6 [12237898.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1293-8 [12375037.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):1059-62 [12792770.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):113-8 [12925965.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Int J Cancer. 1992 Aug 19;52(1):34-7 [1323539.001]
  • [Cites] Diagn Mol Pathol. 1992 Dec;1(4):246-55 [1342973.001]
  • [Cites] Virology. 1992 Sep;190(1):168-75 [1356286.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Oncol Rep. 2004 Sep;12(3):543-7 [15289835.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1093-8 [15492798.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):27-30 [15609391.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Mar;24(1):49-54 [15943031.001]
  • [Cites] Malays J Pathol. 2003 Jun;25(1):45-7 [16196377.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1736-42 [16217758.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):359-63 [16236000.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):379-85 [16270524.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):547-53 [16471317.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] Virology. 1991 Nov;185(1):67-71 [1656606.001]
  • [Cites] Diagn Pathol. 2006;1:5 [16759358.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Virology. 1990 Jul;177(1):44-53 [2162115.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] J Virol. 1990 Sep;64(9):4084-92 [2166806.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):761-5 [2571010.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] J Virol. 1988 Oct;62(10):3862-6 [2901499.001]
  • [Cites] Virology. 1985 Nov;147(1):99-109 [2998075.001]
  • [Cites] Virology. 1986 Oct 15;154(1):56-66 [3019008.001]
  • [Cites] J Virol. 1987 May;61(5):1310-7 [3033261.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):721-8 [6293523.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):607-11 [7827592.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):642-4 [7860138.001]
  • [Cites] Hum Pathol. 1995 Mar;26(3):267-71 [7890276.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):73-81 [8041121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Acta Pathol Jpn. 1993 Oct;43(10):574-81 [8291445.001]
  • [Cites] Blood. 1993 Jul 15;82(2):619-24 [8392401.001]
  • [Cites] Cancer. 1996 May 15;77(10):2137-49 [8640683.001]
  • (PMID = 17629938.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1949397
  •  go-up   go-down


65. Herath CH, Chetty R: Epstein-Barr virus-associated lymphoepithelioma-like gastric carcinoma. Arch Pathol Lab Med; 2008 Apr;132(4):706-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated lymphoepithelioma-like gastric carcinoma.
  • This article provides an overview of the pathology of Epstein-Barr virus (EBV)-associated lymphoepithelioma-like gastric carcinoma, highlighting its unique morphology and clinical features.
  • Lymphoepithelioma-like gastric carcinoma is a rare neoplasm of the stomach with a better prognosis than conventional adenocarcinoma.
  • Most lymphoepithelioma-like gastric carcinomas are associated with EBV infection, while a subset is associated with microsatellite instability.
  • Distinctive histology and demonstration of EBV using in situ hybridization, polymerase chain reaction, or Southern blotting and immunohistochemistry for the DNA mismatch repair genes or polymerase chain reaction analysis of microsatellite loci to assess microsatellite instability helps to make the diagnosis.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384225.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 40
  •  go-up   go-down


66. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol; 2006 Aug;10(4):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology. Racemases and Epimerases / metabolism. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844561.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


67. Omori Y, Nakayama F, Li D, Kanemitsu K, Semba S, Ito A, Yokozaki H: Alternative lengthening of telomeres frequently occurs in mismatch repair system-deficient gastric carcinoma. Cancer Sci; 2009 Mar;100(3):413-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative lengthening of telomeres frequently occurs in mismatch repair system-deficient gastric carcinoma.
  • In this study, we investigated the telomere maintenance mechanism in gastric carcinoma.
  • In formalin-fixed and paraffin-embedded sections of the high frequency of microsatellite instability (MSI-H) and non-MSI-H gastric carcinomas, there was no difference in telomere length monitored by telomere intensity ratio using telomere-fluorescent in situ hybridization.
  • Immunoreactivity of hTERT, the catalytic subunit of telomerase, was detected in 48% of MSI-H gastric carcinomas.
  • The frequency was significantly lower than that in non-MSI-H gastric carcinomas (86%, P = 0.02).
  • Conversely, the number of the alternative lengthening of telomeres-associated promyelocytic leukemia bodies (APBs) detected by combined promyelocytic leukemia immunofluorescence and telomere-fluorescent in situ hybridization was statistically higher (57%) in the MSI-H gastric carcinomas compared to that in non-MSI-H gastric carcinomas (19%, P = 0.026).
  • The cases with hTERT(+)APBs(-) were more frequent in non-MSI-H gastric carcinomas (76%) than in MSI-H gastric carcinomas (24%), and the cases with hTERT(-)APBs(+) were more frequent in MSI-H gastric carcinomas (33%) than in non-MSI-H gastric carcinomas (10%).
  • Defects of the mismatch repair system may lead to homeologous recombination of telomeric ends for the telomerase-independent telomere maintenance in gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Mismatch Repair. Microsatellite Instability. Stomach Neoplasms / genetics. Telomerase / metabolism. Telomere / metabolism
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154407.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


68. Callacondo D, Ganoza-Salas A, Anicama-Lima W, Quispe-Mauricio A, Longacre TA: Primary squamous cell carcinoma of the stomach with paraneoplastic leukocytosis: a case report and review of literature. Hum Pathol; 2009 Oct;40(10):1494-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we describe a case of primary squamous cell carcinoma arising in the gastric antrum of an 83-year-old man with persistent leukocytosis, which resolved on resection of the tumor.
  • Immunohistochemical and in situ hybridization studies for human papillomavirus and Epstein-Barr virus were negative.
  • This case suggests that gastric squamous cell carcinoma likely arises in the setting of long-standing, chronic inflammation, and like squamous cell carcinoma in other organ systems, may be associated with paraneoplastic leukocytosis.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged, 80 and over. Diabetes Mellitus, Type 2 / complications. Humans. Hypertension / complications. Immunohistochemistry. In Situ Hybridization. Male. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2010 Feb;41(2):307. Callacondo-Riva, David [corrected to Callacondo, David]
  • (PMID = 19467693.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res; 2009;28:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A.
  • BACKGROUND: Epstein-Barr virus (EBV) has been shown to be associated with gastric cancer.
  • However, inconsistent findings have been reported regarding the distribution of EBV infected cells (in normal gastric epithelium vs. intestinal metaplastic cells vs. in neoplastic cells) and the characteristics of EBV-associated gastric cancer.
  • Lymph node positive EBV-associated gastric cancer has not been systematically studied.
  • The aims of this study were to evaluate EBV-associated gastric cancer, to assess the distribution of EBV infected cells including all positive lymph nodes, and to define the characteristics of EBV-associated gastric cancer.
  • DESIGN: The study included primary gastric cancer patients who underwent surgical resection with no preoperative treatment at M.D.
  • Formalin-fixed paraffin-embedded tissue from these resection specimens were assessed for EBV by in situ hybridization, the gold standard for EBV detection in tissue.
  • EBV staining was seen only in tumor cells and no detectable EBV was observed in normal gastric mucosa, intestinal metaplasia or stromal cells.
  • Eight of 12 patients with EBV-associated gastric cancer had regional lymph node metastasis.
  • The epidemiologic data showed 11 of the 12 patients with EBV-associated gastric cancer were men, ranging in age from 54 to 78 years (mean age, 60 years; median age, 62.1 years).
  • The age distribution for non-EBV associated gastric cancer patients ranged from 21 to 93 years (mean age, 67 years; median age, 66.4 years).
  • CONCLUSION: Our study demonstrated that EBV is present exclusively in gastric cancer cells.
  • The detection of EBV in tumor cells in all of the lymph nodes involved with metastatic gastric carcinoma suggests simultaneous replication of EBV and tumor cells.
  • The predominantly male gender and relatively younger age observed for the EBV-infected gastric cancer cases suggest an association between this disease and other factors, such as life style.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / virology. Tumor Virus Infections / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gastric Mucosa / virology. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / biosynthesis. Retrospective Studies. Risk Factors. United States. Viral Matrix Proteins / biosynthesis. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1063-71 [8214002.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):805-9 [8039108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Histopathology. 1994 Oct;25(4):323-9 [7835837.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] J Pathol. 1997 Nov;183(3):293-8 [9422984.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] J Med Virol. 2001 Aug;64(4):513-8 [11468737.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):612-8 [11522745.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):33-40 [14550950.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):201-11 [14639106.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):487-91 [15113855.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • (PMID = 19192297.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2642773
  •  go-up   go-down


70. Xiao JH, Fang N, Liu ZL, Chen DX: [Investigation on antitumor mechanism of polysaccharide from medicinal fungus Penicillium jiangxiense]. Zhong Yao Cai; 2008 Jan;31(1):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Both MPPJ4 and MPPJ5, the fine polysaccharide fractions from P. jiangxiense, showed slight cytotoxic effects to inhibit human gastric adenocarcinoma SGC-7901 cells proliferation, but significantly caused cell cycle arrest at the S phase, and the rate of cell population at the subG1 phase was evidently increased.
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Humans. In Situ Nick-End Labeling

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18589753.001).
  • [ISSN] 1001-4454
  • [Journal-full-title] Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
  • [ISO-abbreviation] Zhong Yao Cai
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Polysaccharides
  •  go-up   go-down


71. Geng M, Yin YC, Cao YC, Fu ZJ, Wang XY, Tai YH: [Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA]. Zhonghua Zhong Liu Za Zhi; 2007 Nov;29(11):838-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA].
  • OBJECTIVE: To evaluate in vitro antitumor effects of chemotherapeutic drugs, and investgate the relationship with expression of hTERT mRNA in human gastric cancer tissues.
  • METHODS: Fresh samples of gastric cancer obtained from operation room were prepared to single-cell suspension (3 x 10(5) to 5 x 10(5) cells ml(-1)) and were separately exposed to taxol (TAX), cisplatin (CDDP), 5-fluorouracil (5-Fu), adriamycin (ADM), mitomycin (MMC) for 48 hours.
  • Expression of hTERT mRNA was detected by in situ hybridization (ISH).
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Stomach Neoplasms / pathology. Telomerase / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Cisplatin / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Fluorouracil / pharmacology. Humans. Male. Middle Aged. Mitomycin / pharmacology. Paclitaxel / pharmacology. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396642.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Messenger; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Chong Y, Shin JJ, Cho MY, Cui Y, Kim HY, Park KH: Synchronous primary gastric mantle cell lymphoma and early gastric carcinoma: a case report. Pathol Res Pract; 2008;204(6):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary gastric mantle cell lymphoma and early gastric carcinoma: a case report.
  • We experienced a case of synchronous early gastric cancer (EGC) with primary gastric MCL found as a single early lesion rather than as multiple lymphomatous polyposis.
  • Microscopically, monotonous small- to medium-sized atypical lymphocytes with angulated nuclei formed a mass beneath the gastric mucosa.
  • This is the first case of an EGC accompanying a primary gastric MCL.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphoma, Mantle-Cell / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged


73. Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W: Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer; 2008 Apr 15;112(8):1688-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions.
  • BACKGROUND: Upper gastrointestinal adenocarcinomas are a common cause of cancer-related deaths.
  • In this study, the authors investigated the prevalence and biological significance of Aurora Kinase A (AURKA) overexpression in upper gastrointestinal adenocarcinomas.
  • METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining on tumor tissue microarrays (TMA) were used to study the expression of AURKA in upper gastrointestinal adenocarcinomas.
  • To investigate the biological and signaling impact of AURKA, the authors used multiple in vitro assays that included 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), TUNEL (terminal deoxynucleotidyl transferase-mediated nick-end labeling), cytochrome C release, flow cytometry, luciferase reporter, and Western blot analysis.
  • RESULTS: Frequent overexpression of AURKA transcript in upper gastrointestinal adenocarcinomas was detected compared with normal samples (47%; P= .001).
  • The immunohistochemical analysis of 130 tumors demonstrated moderate-to-strong immunostaining of AURKA in >50% of upper gastrointestinal adenocarcinomas.
  • By using camptothecin as a drug-induced apoptosis in vitro model, the authors demonstrated that the expression of AURKA provided protection against apoptosis to gastrointestinal cancer cells (AGS and RKO) (P= .006) and RIE-1 primary intestinal epithelial cells (P= .001).
  • The AURKA overexpression mediated an increase in phosphorylation of AKT(Ser473) with an increase in HDM2 level.
  • The shRNA-knockdown of AKT in AURKA-overexpressing cells reversed this effect and showed a significant increase in the p53 protein level, indicating a possible nexus of AURKA/AKT/p53.
  • Indeed, overexpression of AURKA led to a remarkable reduction in the transcription activity of p53, with subsequent reductions in transcript and protein levels of its downstream proapoptotic transcription targets (p21, BAX, NOXA, and PUMA).
  • CONCLUSIONS: Study results indicated that AURKA provides potent antiapoptotic properties to gastrointestinal cells by regulating levels of p53 through the AKT/HDM2 axis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Cell Res. 2006 Apr;16(4):356-66 [16617331.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):370-3 [11291073.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):483-92 [11847097.001]
  • [Cites] Nat Med. 2002 Mar;8(3):282-8 [11875500.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9 [12208897.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1173-82 [12390251.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):273-91, viii [12424850.001]
  • [Cites] Med Clin North Am. 2002 Nov;86(6):1423-45, vii [12510459.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):51-62 [12559175.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):281-94 [12707311.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):267-80 [12719470.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2913-22 [12782598.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):55-62 [14702041.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28367-74 [15102863.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Science. 1997 Jan 31;275(5300):661-5 [9005851.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1595-606 [9032287.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3052-65 [9606188.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1091-7 [15286003.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1631-9 [15547700.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):5975-83 [15536123.001]
  • [Cites] Genes Cells. 2005 Jun;10(6):617-26 [15938719.001]
  • [Cites] FEBS Lett. 2005 Jun 20;579(16):3385-91 [15922328.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6583-92 [16061638.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8732-47 [16166651.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11310-6 [11115495.001]
  • (PMID = 18311783.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / CA 95103; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Enzyme Inhibitors; 0 / Luminescent Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Protein p53; 298-93-1 / thiazolyl blue; 9007-43-6 / Cytochromes c; EC 1.13.12.- / Luciferases; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS576419; NLM/ PMC4030394
  •  go-up   go-down


74. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • AIM: To investigate the extent of oxidative stress in pre-neoplastic and neoplastic gastric mucosa in relation to their pathological criteria and histological subtypes.
  • METHODS: A total of 104 gastric adenocarcinomas from 98 patients (88 infiltrative and 16 intraepithelial tumors) were assessed immunohistochemically for expression of iNOS and occurrence of nitrotyrosine (NTYR)-containing proteins and 8-hydroxy-2'-deoxyguanosine (8-OH-dG)-containing DNA, as markers of NO production and damages to protein and DNA.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


75. Bouché O, Penault-Llorca F: [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer; 2010 Dec;97(12):1429-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
  • HER2 protein overexpression by immunohistochemistry (IHC) and/or erB2 gene amplification by in situ hybridization (ISH) was detected in 4-28% of gastric or gastro-oesophageal junction (GOJ) cancers.
  • Most studies have shown that HER2-overexpressing gastric cancers were worse prognosis.
  • The international randomized trial ToGA study showed the superiority of the combination of trastuzumab with chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) plus cisplatin (FP) every three weeks compared with chemotherapy alone in terms of overall survival : 13.8 versus 11.1 months (HR: 0.74, 95% CI: 0.60-0.91, P = 0.0046) in HER2+ advanced gastric cancers.
  • Trastuzumab plus FP chemotherapy has become the standard treatment for patients with HER2+ non-pretreated metastatic adenocarcinoma of the stomach or GOJ cancer.
  • Endoscopic gastric biopsies should be multiple.
  • The standardized immunohistochemical scoring system differs from that recommended for breast cancer given the heterogeneity of HER2 expression and the frequency of incomplete membranous staining in gastric cancers.
  • Equivocal IHC2+ tumours should be tested by ISH with two tools: fluorescence in situ hybridization (FISH) or bright field in situ hybridization (SISH).
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Cisplatin / administration & dosage. Cisplatin / contraindications. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Paraffin Embedding. Randomized Controlled Trials as Topic. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134821.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


76. Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ: Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec (Hoboken); 2009 Aug;292(8):1114-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer.
  • We have investigated the correlations among hepatocyte growth factor (HGF) mRNA expression, basic fibroblast growth factor (bFGF) mRNA expression, tumor microvessel density (MVD), and clinical pathological features of gastric cancer in Chinese patients.
  • In situ hybridization was used to detect the expression of HGF and bFGF mRNAs, and immunohistochemistry was used to detect CD34 in 105 gastric cancer tissues and in 20 normal control tissues.
  • The rate of HGF mRNA expression in normal gastric tissues (25%) was significantly lower than that (57.1%) in tumor tissues (P < 0.01).
  • Both HGF and bFGF may participate in angiogenesis in gastric cancer and may be involved in tumor invasion and metastasis.
  • HGF and bFGF mRNA expression can be used as useful parameters to evaluate the prognosis of gastric cancer.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Antigens, CD34 / metabolism. Endothelial Cells / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neovascularization, Pathologic. Prognosis. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19533745.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 103107-01-3 / Fibroblast Growth Factor 2; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


77. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P: Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res; 2008 Jun 15;68(12):4623-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer.
  • Recurrent genomic amplifications and deletions are frequently observed in primary gastric cancers (GC).
  • RAB23 amplifications in primary gastric tumors were confirmed by both fluorescence in situ hybridization and genomic qPCR, and in two independent patient cohorts from Hong Kong and the United Kingdom RAB23 expression was significantly associated with diffuse-type GC (dGC) compared with intestinal-type GC (iGC).
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Movement. Chromosome Mapping. Chromosomes, Artificial, Bacterial. Cohort Studies. Female. Gene Amplification. Gene Dosage. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genomics. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559507.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.6.1.- / RAB23 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


78. Anwar M, Koriyama C, Naveed IA, Hamid S, Ahmad M, Itoh T, Minakami Y, Eizuru Y, Akiba S: Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan. J Exp Clin Cancer Res; 2005 Sep;24(3):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan.
  • To examine the potential role of Epstein-Barr virus (EBV) in the carcinogenesis of upper gastrointestinal tract, we conducted an in situ hybridization assay for EBV-encoded small RNA (EBER) expression in the tumors of 56 oral and 50 esophageal squamous cell carcinoma (SCC) cases, and 52 stomach adenocarcinoma cases diagnosed in the King Edward Medical College and Allama Iqbal Medical College Lahore, Pakistan between 1996-2002.
  • Only one out of the 52 gastric adenocarcinoma cases (1.9%) was positive for EBER expression, and this frequency was relatively low as compared to cases reported worldwide.
  • The case was a 42 year-old male patient and histologically classified as moderately differentiated tubular adenocarcinoma.
  • In conclusion, the frequency of EBV-associated gastric carcinoma was relatively low in Pakistan.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Gastrointestinal Neoplasms / virology. Herpesvirus 4, Human / isolation & purification
  • [MeSH-minor] Adult. Base Sequence. DNA Probes. Female. Humans. In Situ Hybridization. Male. Middle Aged. Pakistan

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270524.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


79. Szkaradkiewicz A, Majewski W, Wal M, Czyzak M, Majewski P, Bierła J, Kuch A: Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma. Virus Res; 2006 Jun;118(1-2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma.
  • In the presented studies p53 protein expression was evaluated in samples of gastric carcinoma originating from 32 selected adult patients (with documented diagnosis of adenocarcinoma of the stomach and without the presence of Helicobacter pylori infection).
  • Among the patients 14 individuals carried EBV-positive gastric carcinoma (group 1) while the 18 remaining patients carried EBV-negative gastric carcinoma (group 2).
  • EBV infection was detected testing the tissue material for the presence of EBER by RNA in situ hybridization (ISH) and testing sera of the patients for EBV-specific antibodies.
  • Presence of p53 protein was noted in 9 (64.3%) cases of EBV-positive gastric cancer (group 1) and in 10 (55.5%) cases of EBV-negative gastric cancer (group 2).
  • The results permit to conclude that abnormalities in p53 in gastric cancer are independent of EBV infection, even if EBV may participate in development of the tumour.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Antibodies, Viral / blood. Female. Herpesvirus 4, Human. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413625.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


80. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpção PP, Faria MH, Rabenhorst SH, Ferreira MV, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol; 2006 Oct 14;12(38):6207-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.
  • AIM: To investigate chromosome 8 numerical aberrations, C-MYC oncogene alterations and its expression in gastric cancer and to correlate these findings with histopathological characteristics of gastric tumors.
  • METHODS: Specimens were collected surgically from seven patients with gastric adenocarcinomas.
  • Immunostaining for C-MYC and dual-color fluorescence in situ hybridization (FISH) for C-MYC gene and chromosome 8 centromere were performed.
  • CONCLUSION: Distinct patterns of alterations between intestinal and diffuse types of gastric tumors support the hypothesis that these types follow different genetic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aneuploidy. Brazil. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1998 Nov;107(1):61-4 [9809036.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):140-8 [10409442.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):157-62 [10409444.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Braz J Med Biol Res. 2004 Dec;37(12):1831-8 [15558189.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] J Korean Med Sci. 1999 Oct;14(5):526-30 [10576148.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):97-103 [10704677.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Histopathology. 2001 Feb;38(2):111-9 [11207824.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):403-6 [11819799.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):23-7 [12072199.001]
  • [Cites] J Cell Mol Med. 2002 Apr-Jun;6(2):151-9 [12169201.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):66-9 [12550762.001]
  • [Cites] Cytopathology. 2003 Feb;14(1):5-11 [12588304.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):E3 [12671026.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1759-62 [15188501.001]
  • [Cites] Nature. 1983 Nov 10-16;306(5939):194-6 [6646201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4834-8 [3014513.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Recent Results Cancer Res. 1994;136:179-202 [7863095.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):226-32 [9010095.001]
  • [Cites] J Pathol. 1997 Apr;181(4):381-6 [9196434.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):119-21 [9408311.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):896-903 [9462237.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Lab Invest. 1998 Sep;78(9):1143-53 [9759658.001]
  • (PMID = 17036397.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088119
  •  go-up   go-down


81. Baldus SE, Mönig SP, Zirbes TK, Thakran J, Köthe D, Köppel M, Hanisch FG, Thiele J, Schneider PM, Hölscher AH, Dienes HP: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol; 2006 05;21(5):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters.
  • Therefore, we tried to elucidate its clinicopathological relevance in a series of 160 gastric and 215 colorectal carcinomas by immunohistochemical detection of Le(y) and visualization of apoptotic cells applying the in-situ-end labelling (ISEL) method, followed by semiquantitative scoring of the specimens.
  • In both gastric as well as colorectal carcinomas, between 40 and 50% of the cases were Le(y) reactive.
  • [MeSH-major] Adenocarcinoma / immunology. Apoptosis. Carcinoma, Signet Ring Cell / immunology. Colorectal Neoplasms / immunology. Lewis Blood-Group System / analysis. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493580.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


82. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL: Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology; 2008 Feb;52(3):314-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To investigate the in situ expression profile of glucocorticoid receptor (GR) in normal and carcinomatous tissues of the human digestive system.
  • Consistently, GR expression was found in a high percentage of oesophageal squamous cell carcinomas (SCC) (98.1%) and hepatocellular carcinomas (HCC) (92.9%), but rarely in gastric adenocarcinomas (7.4%) and not at all in colorectal adenocarcinomas (0%).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Basosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Digestive System Neoplasms / metabolism. Receptors, Glucocorticoid / metabolism

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269582.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Receptors, Glucocorticoid; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


83. Wang GR, Zheng Y, Che XM, Wang XQ, Wang XW, Pan CE, He WX: [Expression of heparin-binding epidermal growth factor-like growth factor in patients with gastric carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):44-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of heparin-binding epidermal growth factor-like growth factor in patients with gastric carcinoma].
  • OBJECTIVE: To investigate the expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF) in patients with gastric carcinoma in different stages.
  • METHODS: The expressions of HB-EGF protein and mRNA in normal gastric tissues, metaplasic intestinal mucosa, early-stage gastric cancer and advanced-stage gastric cancer tissues were detected by immunohistochemistry and in situ hybridization.
  • RESULTS: HB-EGF expression was only detected in the parietal cells of the gastric fundic glands and in gastrin cells of the pyloric glands in normal gastric tissues.
  • Weak HB-EGF expression was detected in the epithelial cells of the gastric mucosa in intestinal metaplasic mucosa, and the expression increased in all layers of the gastric mucosa in early-stage gastric cancer.
  • Intense HB-EGF expression was observed in advanced gastric cancer.
  • CONCLUSION: Increased HB-EGF expression may be implicated in the pathogenesis and development of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gastric Mucosa / metabolism. Heparin-binding EGF-like Growth Factor. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218109.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.